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ABSTRACT 
The purpose of the project was to increase healthcare professionals’ knowledge regarding 
HPV, the vaccine, and communication strategies to improve vaccine acceptance. In addition, the 
purpose was to increase healthcare professionals’ level of comfort in using the communication 
strategies discussed. The project was also designed to reduce HPV vaccination rates of missed 
opportunities and increase overall HPV vaccination coverage. The rates of HPV vaccination 
coverage are significantly lower than other adolescent vaccines. There has been minimal 
research on the impact of an educational intervention in rural areas. A literature review was 
performed prior to project design and implementation, which revealed the significance of 
providing healthcare professional education.  
An educational intervention was performed in two rural family practice clinics in North 
Dakota. Post-test questionnaires were collected to evaluate healthcare professional knowledge 
and comfort using a 5-point Likert scale. HPV vaccination and missed opportunity rates were 
monitored for two months before and after the intervention. The results of the questionnaire 
revealed an average Likert score of 3.97 for increased understanding of HPV, the vaccine, and 
communication strategies. The average Likert score for increased comfort with the new 
communication strategies was 4.06. The number of missed opportunities at routine exams, 
including well child and physical exams, was reduced from 32 in the two months prior to 
implementation of the educational intervention to only 17 in the two months after 
implementation at one of the rural clinics. No change was noted in overall HPV vaccination rates 
or missed opportunities. In conclusion, further research is needed to understand the type of 
education required for reduced HPV vaccination rates and sustainability. Continued research 
should also evaluate the impact of a multifaceted approach to improve HPV vaccination rates. 
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CHAPTER 1. INTRODUCTION 
Background and Significance  
 Every year in the United States (U.S.), over 30,000 people are diagnosed with human 
papillomavirus (HPV)-related cancers (Center for Disease Control and Prevention [CDC], 
2016a). HPV is a sexually transmitted infection with over 150 different serotypes of the virus, 
which is estimated to infect 14 million people each year in the U.S. This adds to the growing 
number of almost 80 million people who are currently infected with at least one strain of HPV. 
With these statistics in mind, it is vital to understand the complications of an HPV 
infection. Most HPV infections clear without the need for treatment; however, some infections 
last longer and are linked with serious complications. Cervical, vaginal, vulvar, penile, anal, and 
oropharyngeal cancers are all associated with HPV infections (CDC, 2016a). Additionally, a 
person infected with HPV often does not show any signs or symptoms and continues to pass the 
virus on to others without even knowing the danger exists until complications arise. 
Since HPV infections are quite common and complication rates are rising due to the 
increasing number of infections, the question of what can be done arises. Fortunately, there is a 
vaccination against HPV that provides protection against nine serotypes. The first quadrivalent 
HPV vaccine was released over ten years ago in 2006. The 9-valent HPV vaccine was licensed in 
2014 for use in both females and males and is now the only available HPV vaccine approved by 
the Food and Drug Administration (FDA) (CDC, 2016b). There are currently no 
recommendations for revaccination with the 9-valent HPV vaccine if a person completed the 
HPV vaccine series with quadrivalent or bivalent HPV vaccines. 
The Advisory Committee on Immunization Practices (ACIP) recommends the vaccine be 
administered to females and males between the ages of 11 to 12 years; however, the vaccine is 
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approved for ages 9 through 26 years (Meites, Kempe, & Markowitz, 2016). There are two 
separate dosing schedules depending upon when the vaccine is initiated. If initiated before 15 
years of age, only two doses are required to be given six months apart. If the vaccine is initiated 
after 15 years, a three-dose scheduled is required. 
While the HPV vaccine has been in existence for over ten years, vaccination uptake 
continues to lag. One of the objectives of Healthy People 2020 is to increase vaccination 
coverage to a target of 80 % for the HPV vaccine, along with all others (Office of Disease 
Prevention and Health Promotion [ODPHP], 2018). According to the CDC (2018a), roughly 60 
% of teens in the United States, both male and female, ages 13 to 17 years received at least one 
dose of the HPV vaccine. The number of adolescents and young adults who received at least one 
dose of the HPV vaccine ranged from 41.9 to 88.9 among various states with the percentage in 
North Dakota being 67.6% (CDC, 2017a). In comparison to HPV rates, other adolescent vaccine 
coverage rates are much higher. For example, the tetanus-diphtheria-pertussis (TDaP) vaccine 
coverage range in the United States was 77.5% to 96.7% with North Dakota at 92 % (CDC, 
2017b). TDaP is a required vaccine for teens to receive, while the HPV vaccine is a 
recommended vaccine in North Dakota. 
The current coverage rates can be broken down further to evaluate specific counties in 
North Dakota (North Dakota Immunization Information System [NDIIS], 2018). In Stutsman 
County, 73% of adolescents and young adults have received one dose of the HPV vaccine, and 
there is a 93.2% completion rate for the TDaP vaccine. The up-to-date percentage for the HPV 
vaccine, or the percentage of those who are receiving the vaccination series on schedule, drops to 
56.88% for Stutsman County. Barnes County reports a 64.44% coverage rate for one dose and 
54.81% up-to-date for the HPV vaccine. TDaP coverage is 89.23% in Barnes County. 
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The difference in coverage rates between HPV vaccination and the other recommended 
adolescent vaccinations exposes the existence of missed opportunities. A missed opportunity is 
an adolescent visit during which TDaP and MenACWY were administered while the HPV 
vaccine was not (Espinosa et al., 2017). Missed opportunities include well-child visits, as well as 
any other visit in which the adolescent sees a primary care provider. Missed opportunities are an 
ongoing problem according to the CDC and a commonly cited reason for the significantly low 
rates of HPV vaccination coverage (Javaid et al., 2017; Reagan-Steiner et al., 2016). 
HPV vaccination is a significant intervention that can reduced HPV-related 
complications; however, acceptance and HPV vaccination coverage rates continue to lag behind 
other recommended adolescent vaccinations, including TDaP and MenACWY. The existence of 
missed opportunities and barriers require action. Interventions need to be done to improve 
provider knowledge of effective communication strategies regarding the HPV vaccine, reducing 
missed opportunities, eliminating misperceptions of the vaccine, and decreasing barriers to 
vaccination. 
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CHAPTER 2. REVIEW OF LITERATURE 
 With the knowledge of the current problem with low HPV vaccination coverage, a 
practice improvement project is indicated. The first step in creating a project is to ensure it is 
evidence-based. A systematic search was performed using the following databases: The 
Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Database of 
Systematic Reviews (CDSR), PubMed, Medline, and Health Source: Nursing/Academic 
Education. A keyword search was performed and included: human papillomavirus, HPV, 
education, communication strategies, vaccine, vaccination, complications, cancer, barriers, 
andragogy, parent, knowledge, safety, efficacy, adverse events. Various word combinations were 
used in the database searches with numerous articles found. The articles were critically appraised 
for applicability and reliability. After appraisal, key topics were developed and will be discussed 
further, including HPV epidemiology, complications, the HPV vaccine, vaccination coverage 
data, barriers to vaccination coverage, missed opportunities, and strategies to improve HPV 
vaccination coverage. 
HPV Epidemiology 
 Human papillomavirus is a virus specific to humans, which attacks epithelial cells and 
mucous membranes (Dunphy, Winland-Brown, Porter, & Thomas, 2015). There are over 150 
serotypes of HPV. There are two main categories of HPV serotypes: low-risk and high-risk. 
Low-risk serotypes can cause plantar or genital warts. Type 1 is known to cause plantar warts, 
whereas types 6 and 11 cause anogenital warts. High-risk serotypes are linked with progressive 
neoplasms and include Type 16 and 18. The serotypes causing genital warts and cancer are 
transmitted through intimate contact, including oral, anal, and vaginal sex (CDC, 2016c). HPV 
infections are extremely common with an estimated 80% of Americans being infected in their 
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lifetime. Many of the 150 serotypes can be cleared without concern; however, approximately 
10% of HPV infections will not be cleared by the immune system, leading to persistent infection 
and serious consequences. 
Pathophysiology 
 Persistent HPV infections are a known cause of cervical, anal, vaginal, vulvar, penile, and 
oropharyngeal carcinomas (Viens et al., 2016). Serotypes 16 and 18 are linked with over 73% of 
HPV-related cancers (de Martel, Plummer, Vignat, & Franceschi, 2017). These serotypes, along 
with other high-risk serotypes, infect the basal cells of squamous epithelia through 
microabrasions or wounds (Maxwell, Grandis, & Ferris, 2016). Once the infection occurs, the 
virus replicates and differentiates. HPV can survive in a latent state for decades before 
undergoing any malignant transformation allowing it to evade immune system defenses. 
Oncoproteins E6 and E7 are key factors related to the malignant transformation by inactivating 
tumor suppressor proteins in the body. 
Complications 
 When considering the epidemiology of HPV infections, it is essential to look at each of 
the associated complications. Both genital warts and cancer are associated complications of 
persistent HPV infection. There are now several known cancers associated with HPV infection, 
including cervical, oropharyngeal, anal, vaginal, vulvar, and penile. The associated annual 
medical costs for HPV-related complications in the United States are estimated to be $8 billion 
(Dahlstrom et al., 2018). The direct medical costs in the United States for treating HPV-related 
genital warts, a low-risk complication, for two years after diagnosis is approximately $6,700. 
Genital warts. HPV 6 and 11 are both serotypes linked with causing approximately 85% 
of anogenital warts (Joura & Pils, 2016). Both sexes are affected by anogenital warts, with a 
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lifetime risk of 10%. Warts are considered to be low-risk HPV complications (Daughtery & 
Byler, 2018). Qi et al. (2014) reported a negative impact on quality of life for patients with 
genital warts, specifically noting increased concerns about self-image and a great psychosocial 
burden. Anogenital warts do require large amounts of patient education about their cause and 
treatment. Aggressive partner follow-up is encouraged to reduce the spread of HPV, as it can 
become resistant to treatment and have a lifetime impact (Dunphy et al., 2015). 
 Cervical cancer. The link between cervical cancer and HPV infection has been 
established for several years, yet the worldwide rates of cervical cancer remain high. According 
to de Martel et al. (2017), cervical cancer accounts for a staggering 83% of the new HPV-related 
cancer cases each year with a majority of those cases in less developed countries. Females under 
the age of 50 years are impacted the most by cervical cancer with an estimated 250,000 cases 
diagnosed globally each year. North America accounts for 14,000 of the worldwide cases of 
cervical cancer each year.   
The age of the female during infection with HPV is also a key factor of cervical cancer 
epidemiology (Hacker, Gambone, & Hobel, 2016). The adolescent cervix is at a higher risk of 
carcinogenic stimuli from frequent infections due to the active process of squamous metaplasia. 
Mirabello et al. (2018) found HPV 16 to be the most carcinogenic but noted variants of HPV 16 
create different risks of persistence and progression of the infection. Continued genomics and 
epidemiology research is being done to better understand the subvariants and associated risk 
levels. 
Oropharyngeal cancer. A newer HPV-related cancer on the rise is oropharyngeal cancer 
(Selcuk, 2016). The overall incidence of head and neck squamous cell cancer is declining in 
developed countries; however, HPV-related oropharyngeal squamous cell carcinoma (OPSCC) 
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continues to increase. The impact of HPV-related OPSCC is predicted to increase and be larger 
than that of HPV-related cervical cancer by the year 2020. HPV prevalence has increased from 
16.3% between 1984 and 1989 up to an overwhelming 71.7% between 2000 and 2004 (Maxwell, 
Grandis, & Ferris, 2016). De Martel et al. (2017) report a higher burden of HPV-related head and 
neck cancers in developed countries than less developed countries, which is opposite that of 
HPV-related anogenital cancers. Alcohol and tobacco use are known risk factors for HPV-
negative OPSCC, but they are no longer the leading cause of OPSCC (Maxwell et al.., 2016). 
The leading cause is now HPV infection. 
With the predicted impact of HPV-related OPSCC in mind and increased burden in 
developed countries, it is important to note the prognosis. Maxwell et al. (2016) describe a 
superior three-year survival rate with HPV-negative OPSCC. The tumors respond better to all 
types of treatment being used. Better local and regional control of the cancer is seen; however, 
distant metastatic control was similar for both HPV positive and negative OPSCC. 
 Anal cancer. Another known complication of HPV infection is anogenital cancers, one 
of which is anal cancer. An estimated 88% of invasive anal cancer cases are attributable to HPV 
infection worldwide (Serrano et al., 2015). According to de Sanjosé, Bruni, and Alemany (2014), 
roughly 91.1% of invasive anal cancers in the United States were positive for HPV. A higher 
incidence is seen in women than men, as there are approximately 18,000 new female cases and 
17,000 new male cases annually (de Martel et al., 2017). Serrano et al. (2015) report 87% of the 
HPV positive anal cancers to be positive for HPV 16 and 18, which are two of the known high-
risk serotypes. HPV 16- and 18-related tumors tend to be more aggressive in comparison to other 
HPV positive tumors and are seen to develop at earlier ages. 
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Vulvar and vaginal cancers. Vulvar and vaginal cancers are also attributable to HPV 
infection with 8,500 and 12,000 new cases worldwide annually (de Martel et al., 2017). North 
America accounts for 3,300 of these new cases, as both vulvar and vaginal HPV-related cancers 
have a higher incidence in less developed countries. Serrano et al. (2015) detected HPV 16 and 
18 in 63.7% of vaginal and 72.6% of vulvar cancers. The next highest serotypes detected were 
HPV 31 in 5.3% of vaginal lesions and HPV 33 in 6.9% of vulvar lesions respectively. Vaginal 
and vulvar cancers account for 4% of all gynecology malignancies, and the majority of these 
cases are consistently related to HPV infection (de Sanjosé et al., 2014). 
 Penile cancer. The final anogenital HPV-related cancer is penile cancer. Penile cancer is 
very rare, representing less than 1% of cancers among men in the United States (de Sousa et al., 
2015). However, the incidence of penile cancer is as high as 10% in some parts of the world. 
Approximately 63.5% of penile lesions were positive for HPV infection with HPV 16 being the 
most common strain, and the glans has been found to be the most common location.  
HPV infection is a known risk factor for causing penile cancer. The prevalence of HPV 
infection is known to vary based on geographic location according to Alemany et al. (2015). The 
variation is believed to be attributed to circumcision practices and their impact with developing 
persistent HPV infections. Additionally, D’Hauwers et al. (2012) note a correlation between the 
incidence of cervical cancer and penile cancer worldwide. 
HPV Vaccine 
 The existence of HPV in cervical cancer samples was discovered in the 1980s (Luckett & 
Feldman, 2016). By 1999, scientists had discovered how persistent HPV infections are linked 
with causing cervical cancer, and later the connection with several other complications was made 
(Joura & Pils, 2016). With the expanding knowledge of the role of HPV and its known 
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complications came the idea to create a vaccine and allow for the implementation of primary 
prevention. The purpose of vaccines is to stimulate the immune system and cause it to produce a 
reaction against the specific infectious agent, which creates protection from the disease without 
having to have it first, which is also known as humoral immunity (Bonanni et al., 2017; Angioli 
et al., 2016). 
Vaccine History 
 The first HPV vaccine became available in 2006, a quadrivalent HPV vaccine (Joura & 
Pils, 2016). Marketed by Merck, it was designed to provide protection against HPV 6, 11, 16, 
and 18 and is also known at Gardasil. In 2007, GlaxoSmithKline released the Cervarix HPV 
vaccine. Cervarix is a bivalent vaccine designed to provide protection against HPV 16 and 18. 
The quadrivalent and bivalent vaccines were the only available options for several years.  
In 2014, Gardasil 9 was approved by the FDA as the only nine-valent HPV vaccine (9vHPV). 
The nine-valent vaccine targets HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58. All three of the 
vaccines are available internationally. Due to recommendations from the CDC and ACIP, the 
nine-valent HPV vaccine is the only available HPV vaccine in the United States as of late 2016 
(Meites, Kempe, & Markowitz, 2016). 
Vaccine Recommendations 
 The nine-valent vaccine is recommended for females and males ages 9 to 26 years with 
an emphasis for initiating the vaccine at 11 to 12 years. Since the approval in 2014, there has 
been one recommended change to the dosing schedule for the nine-valent vaccine. The change to 
the only 9vHPV vaccine occurred with a change in the dosing schedule. Originally, all of the 
vaccines required a 3-dose series. In 2016, a new 2-dose schedule was approved by the ACIP 
(Meites et al., 2016). The 2-dose schedule applies to males and females ages 9 to 14 years. The 
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second dose is given 6 to 12 months after the first. Males and females ages 15 to 26 years and 
those who are immunocompromised are to receive the 3-dose series with the second dose given 1 
to 2 months after the first and the third dose 6 months after the first. The CDC approved the 
change in schedule after an FDA trial. Immune responses to the HPV vaccine after four weeks 
were noninferior for the adolescents ages 9-14 years who received two doses of the vaccine 
when compared to adolescent girls and young women who received the three-dose series of the 
HPV vaccine (Iverson et al., 2016). The trial had over 1500 participants, both males and females. 
The results also demonstrated how immune responses are typically better in young children and 
young adolescents than in adults. 
Efficacy 
 The efficacy of the bivalent and quadrivalent HPV vaccines is established; however, it is 
significant to note it takes several years post recurrent HPV infections for cancer to develop 
(Luckett & Feldman, 2016). All three vaccines have demonstrated high efficacy in HPV-naïve 
females. The bivalent vaccine revealed 92.6% efficacy in preventing HPV16 and 18 cervical 
intraepithelial neoplasia (CIN) 2 lesions or worse in HPV-naïve females in the PATRICIA trial. 
The PATRICIA trial also established 52.8% efficacy in CIN2 lesions in females with a history of 
previous HPV infections. The quadrivalent vaccine’s efficacy was evaluated in the Future II trial 
and demonstrated 98% efficacy in CIN2 or worse lesions in HPV-naïve females and 42% and 
79% efficacy against HPV 16 and 18 in women with a history of previous infections.  
Additionally, the Future I and II trials demonstrated greater than 96% efficacy against HPV-
related vulvar and vaginal cancers as well (Angioli et al., 2016). Ninety percent efficacy was 
established against penile, perianal, and perineal diseases in males after receiving the 
quadrivalent vaccine.  
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The 9vHPV vaccine demonstrated 96% efficacy against HPV 31, 33, 45, 52, and 58 and 
96% against HPV 6, 11, 16, and 18 (Luckett & Feldman, 2016). The efficacy against HPV 6, 11, 
16, and 18 was shown to be noninferior to the quadrivalent vaccine; however, the additional 
serotypes provides increased protection. Currently the bivalent and quadrivalent vaccines 
provide protection against 70% of cervical cancer worldwide (Joura et al., 2015). With the added 
serotypes included in the 9vHPV vaccine, the amount of protection against cervical cancer is 
estimated to increase to 90%. 
Safety and Adverse Events 
 The safety of vaccinations is an ever-present concern for parents and patients. Chandler 
(2017) explains how there are three stages of vaccine pharmacovigilance: signal detection, 
development of a causality hypothesis, and testing of the hypothesis. Rigorous testing and 
surveillance is used with all vaccinations, including HPV vaccines. The FDA also requires a 
three phase process for the development of vaccines, with a fourth phase occurring once the 
vaccine is on the market and available for public use (FDA, 2018). The first phase of vaccine 
trials evaluates the safety and immunogenicity of the vaccine. Phase two assesses the necessary 
dosing for the vaccine. The third phase further evaluates vaccine effectiveness. The process to 
receive FDA vaccine approval for marketing takes several years. Extensive safety evaluations 
and control group trials are done prior to approval and with any changes to recommendations 
(Gonçalves et al., 2014). Angioli et al. (2016) explain how the 9vHPV vaccine is not 100% risk 
free, which is similar to all other medications and vaccinations. FDA monitoring and approval is 
required in the United States. 
 As with other vaccines, adverse events are reported and monitored. The Vaccine Adverse 
Event Reporting System (VAERS) is a database used for reporting unverified adverse events 
 12 
following immunization administration in the United States. The most common adverse event 
reported after receiving the HPV vaccine is pain at the injection site (Angioli et al., 2016). The 
nine-valent vaccine is associated with a slightly higher rate of adverse events in comparison to 
the quadrivalent vaccine. Less than 10% of girls who received the HPV vaccine reported pain, 
which is less than that of other vaccines (Nicol et al., 2015). Gonçalves et al. (2014) found local 
reactions of pain, swelling, and erythema at injection site to be the most common adverse events 
reported in a systematic quantitative review. Systemic adverse events reported were fever, 
nausea, and dizziness. General adverse events were discovered to be not related to receiving the 
HPV vaccine. Furthermore, no absolute contraindications to receiving the vaccine were 
identified. The vaccine is not recommended to be given during pregnancy but is not absolutely 
contraindicated. 
 Serious adverse events are rare according to Luckett and Feldman (2016). Most adverse 
events after receiving any of the HPV vaccines are mild and self-limited. Concerns of 
autoimmune, neurological, and venous thromboembolic (VTE) events have circulated and 
caused resistance to increased vaccination rates (Gonçalves et al., 2014). No safety signals 
related to any of these events were found. 
 Multiple studies have been conducted to further evaluate any link between VTE and the 
HPV vaccine. Lui et al. (2016) investigated HPV vaccine adverse events in Alberta, Canada. 
Over 528,000 doses of HPV vaccine were given during their research, with 192 reports of 
adverse events found or 37.4 per 100,000 doses. None of the reported adverse events were 
consistent with VTE. An additional study conducted by Yih et al. (2016) evaluated the risk of 
VTE after HPV vaccine administration in the United States. Between 2006-2013, 279 potential 
cases of VTE were identified within the defined post-HPV vaccine administration time. After 
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further chart evaluations, the number of definite first VTE cases was narrowed down to 53. 
Additional known VTE risk factors were identified within the cases, including oral contraceptive 
use, blood coagulation disorders, recent surgery, and immobility. Yih et al. (2016) found a lack 
of evidence to indicate any increased risk for VTE after HPV vaccine administration. The lack of 
association found corresponds with the results of other studies as well. Naleway et al. (2015) 
discovered the number of VTE cases after HPV administration to be small and not linked with 
any significant risk increase. 
Autoimmune and neurologic adverse events have also been researched further to have a 
better understanding of any link between vaccination and diagnosis. According to Bonanni et al. 
(2017), there are no research findings to support any link between HPV vaccination and 
demyelinating disease, complex regional pain syndrome, or postural orthostatic tachycardia 
syndrome. Arnheim-Dahlstrröm et al. (2013) conducted an evaluation of over 690,000 doses of 
HPV vaccine administered to over 290,000 girls in Denmark and Sweden. Their results detected 
a slight increased risk for Behcet’s syndrome, Raynaud’s disease, and type I diabetes; however, 
further analysis revealed a lack of consistent evidence to support a claim for causal association 
between the vaccine and the autoimmune conditions. The rates for epilepsy and paralysis were 
noted to be decreased after vaccine administration. No safety signals were identified in the study. 
The evidence suggests the benefits far outweigh the risks for receiving the vaccine series. 
Vaccination Coverage 
 National Vaccination Coverage 
 Despite the recommendations and benefits of receiving the HPV vaccine, vaccination 
coverage remains low in the United States. The 2015 National Immunization Survey-Teen report 
revealed that among adolescents between 13-17 years of age, HPV vaccination coverage with ≥1 
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dose was 56.1% (Reagen-Steiner et al., 2016). The coverage drops significantly with each dose 
of the vaccination given with ≥ 2 doses at 45.4% and ≥ 3 doses at 34.9% for males and females 
combined. When the national coverage rates are divided based on gender, the coverage for males 
receiving ≥1 dose is 49.8% and 62.8% for females. 
The National Immunization Survey-Teen also found differences in coverage between 
Hispanics, non-Hispanic whites, and non-Hispanic blacks (Reagen-Steiner et al., 2016). 
Coverage with ≥1 dose was higher among both Hispanic and non-Hispanic black adolescents 
than non-Hispanic white adolescents. Another characteristic with noted differences in coverage 
rates was living below the federal poverty level. Adolescents living below the federal poverty 
level had increased ≥ 1 dose coverage in comparison to those living at or above the federal 
poverty level with coverage rates for females below the poverty level at 70.0% in comparison to 
females at or above the poverty level at 60.4%. Male coverage rates for receiving ≥1 dose 
coverage at the poverty level was 61.1% versus the 46.0% at or above the poverty level. 
State Vaccination Coverage 
 There is great variation in HPV vaccination coverage among states. For example, HPV 
vaccination coverage varies greatly between the states with Rhode Island reporting ≥1 dose all 
adolescent coverage of 88.9%, yet Wyoming reporting 43.4% for the same population (CDC, 
2018b). North Dakota is in the top twenty for ≥1 dose coverage for both male and female 
adolescents ages 13-17 years with a percentage of 67.6; however, this is still below the 
HealthyPeople 2020 goal of over 80% coverage. Figure 1 demonstrates the coverage of ≥ 1 dose 
of HPV vaccine in the United States. There are areas with consistently increased uptake, 
including California. A factor impacting the uptake rates in California is the strict state 
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immunization policy, which does not allow for personal or religious belief exemptions for 
receiving required vaccinations (National Vaccine Information Center [NVIC], 2018). 
 
 
Figure 1. Human papillomavirus (HPV) vaccination coverage among adolescents 13-17 years by 
state, HHS region, and the United States, National Immunization Survey-Teen (NIS-Teen), 2008 
through 2016. Reproduced from CDC, 2018b. 
 Specifically looking at North Dakota, more information can be obtained about the current 
vaccination rates statewide. The statewide coverage for up-to-date HPV vaccination among 
adolescents ages 13-17 is 52.7%, with 60.2% of that being females and 45.5% males (CDC, 
2018b). The up-to-date coverage rates are almost 15% lower in comparison to the rates for ≥ 1 
dose of HPV vaccine with a greater gap between genders. 
County Vaccination Coverage 
 After evaluating both national and state coverage, additional information can be obtained 
from the North Dakota State Department of Health regarding county coverage rates (NDIIS, 
2018). Further evaluating Stutsman and Barnes Counties disseminates more information about 
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the current coverage rates for Jamestown and Valley City, North Dakota. The rate of ≥1 dose of 
HPV vaccine in Stutsman County for both males and females ages 13- 17 years is 73.07%, while 
the up-to-date coverage is at 59.43%. The percentages differ when evaluating males and females 
separately with 79.09% of females and 68.07% of males receiving ≥ 1 dose and 63.01% of 
females and 48.02% of males being up-to-date. 
The coverage for Barnes County is within the same category as Stutsman; however, the 
percentages are lower (NDIIS, 2018). Sixty-five percent of males and females together have 
received ≥ 1 dose while only 55.64% are up-to-date. The gender differences, although small, 
continue to exist with 65.92% of females and 64.40% of males receiving ≥1 dose and 57.46% of 
females and 53.87% of males being up-to-date. Figure 2 represents the current HPV vaccination 
coverage in North Dakota counties. 
 
Figure 2. Adolescent HPV Immunization Rates Years 13-17. Reproduced from the North Dakota 
Department of Health and the North Dakota Immunization Information System (2018). 
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Coverage Variables 
 Research has found key variables impacting HPV vaccination coverage (Reagan-Steiner 
et al., 2016; Simons, Unger, Lopez, & Kohn, 2015). Gender differences can be seen at the 
national, state, and county levels with females more often receiving the HPV vaccination and 
being up-to-date. The type of insurance whether private, public, or no insurance is another key 
variable. Simons et al. (2015) found more patients with private insurance were receiving the 
HPV vaccinations than those with public insurance. 
Confounding evidence suggests that race may also influence coverage rates. According to 
Reagan-Steiner et al. (2016), HPV coverage was higher among Hispanics and non-Hispanic 
blacks than white adolescents. Simons et al. (2015) reported white adolescents with higher 
coverage rates within family planning centers; however, Asian-Pacific islanders had the highest 
coverage rates. A fourth variable is living below the poverty level. Adolescents living below the 
federal poverty level were found to have higher vaccination coverage rates in comparison to 
those living at or above the poverty level (Reagan-Steiner et al., 2016). Each of these variables 
must be kept in mind when evaluating current coverage rates, as well as devising HPV 
vaccination coverage improvement strategies. 
Required Vaccination Comparison Data 
 With the current HPV vaccination coverage data in mind, a comparison with the required 
school vaccinations provides further details about the status and room for improvement. 
Currently, the tetanus, diphtheria, and acellular pertussis (TDaP) vaccine and quadrivalent 
meningococcal vaccine (MenACWY) are the two required vaccines vaccinations for school-aged 
adolescents. The TDaP vaccine is a one dose vaccine recommended to be given at ages 11-12 
years with a booster Td given every 10 years, unless otherwise recommended (CDC, 2015). The 
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MenACWY vaccine is a 2-dose series with the first dose recommended at ages 11-12 years and a 
booster dose at age 16 years (CDC, 2018c). The CDC (2018d) recommends the TDaP, 
MenACWY, and HPV vaccines be given between ages 11 to 12 years. The recommendation 
allows for a direct comparison of vaccination rates to be done. 
 In 2015, the national coverage of ≥ 1 dose of TDaP was 86.4% for all adolescents ages 
13-17 years (Reagan-Steiner et al., 2016). The coverage of ≥ 1 dose of MenACWY for all 
adolescents was 81.3%. Both required vaccines are above the Healthy People 2020 goal of > 
80% coverage. The lowest coverage rate nationally for TDaP is in South Carolina with a 
percentage of 77.5 for receiving ≥1 dose of TDaP (CDC, 2018e). The highest coverage is found 
in Massachusetts with a staggering 96.7%. When considering North Dakota alone, the TDaP 
coverage is 92% for males and females combined ages 13-17 years. Stutsman and Barnes 
counties have a TDaP rate of 94.25% and 87.99% respectively (NDIIS, 2018). 
The national coverage for MenACWY has a wider range with Wyoming having a rate of 
54.2% of all adolescents receiving ≥1 dose of MenACWY and Rhode Island at the top with 
96.4% (CDC, 2018f). The MenACWY coverage is 92% in North Dakota. These rates are almost 
40% higher than that of HPV vaccination with ≥1 dose. Stutsman and Barnes counties in North 
Dakota have coverage rates for ≥1 dose of MenACWY of 92.55% and 87.41% respectively, 
which are notably higher in comparison with ≥1 dose of HPV vaccination for the same 
adolescent population. Despite the progress of HPV vaccination programs, the coverage rates are 
still far behind, indicating the existence of HPV vaccination barriers and need for improvement. 
Barriers of HPV Vaccination Coverage 
 Since the recommendation for HPV vaccination in 2006, barriers for vaccination 
coverage have been identified (Brown, Hopfer, & Chan, 2015; Tom et al., 2015). HPV 
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vaccination myths, parental concerns, parental knowledge, provider beliefs, missed 
opportunities, and lack of follow-up for vaccination completion are all known barriers. Parental 
concerns include safety issues, beliefs about promoting sexual promiscuity, questions of the 
necessity of the vaccine, and lack of provider recommendations for the vaccine. A better 
understanding of HPV vaccination barriers can lead to the development of quality improvement 
projects and educational programs to improve coverage rates and remove the barriers. 
HPV Vaccination Myths & Parental Concerns 
 HPV vaccination myths and parental concerns are closely linked and often found to 
overlap. Common myths and concerns noted in research are a risk for increased sexual activity 
after receipt of the HPV vaccine, promotion of unsafe sexual practices, lack of vaccine necessity 
due to abstinence, cost and financial concerns, and safety concerns related to the vaccine (Farmar 
et al., 2015). Each myth impacts the provider-parent-adolescent visit and conversation in a 
unique, yet connected way. 
Increased risk of sexual activity and unsafe sexual practices.  The concern for an 
increased risk of sexual activity and promiscuity has been raised by both parents of male and 
female adolescents (Oldach & Katz, 2012). Parents of females noted increased concern in 
comparison to parents of males with reports of the concern roughly 17% of the time when 
discussing the concern with healthcare staff. Farmar et al. (2016) support the existence of the 
barrier as well, noting parental fear that receiving the vaccine will cause their children to become 
sexually promiscuous. 
The link between the myth and parental concern of increased sexual promiscuity is 
related to parental knowledge about HPV infection (Zimmerman et al., 2016). Parents 
understand that transmission of HPV infections is related to sexual activity and believe 
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immunization will cause children to believe the vaccine decreases the risks associated with 
sexual activity, thereby leading to promiscuity. Many parents believe that increased risk of 
promiscuity leads to the practice of unsafe sex practices and additional increased risks. 
The myth and parental concerns related to increased risk for promiscuity and unsafe 
sexual practices have not been proven through research. Brown et al. (2015) reported no 
significant correlation between receipt of the HPV vaccine and increased risk for sexual activity 
or unsafe practices. Despite the lack of evidence, the myth continues to exist, creating a barrier 
for vaccination coverage and improvement. 
Lack of Vaccine Necessity due to Abstinence. The parental belief in the lack of HPV 
vaccination due to necessity relates closely to parental knowledge about HPV and the 
vaccination. Hansen, Credle, Shapiro, and Niccolai (2016) explained how parents often 
underestimate the sexual experience of their children. Parents may rely on cues, adolescent 
characteristics, and common age beliefs when considering their adolescents’ sexual experience 
and activity. A father was noted to express a lack of purpose for the vaccine in a 12-year-old girl 
unless she was sexually active, which he considered to be highly unlikely. According to the 
Youth Risk Behavior Survey (YRBS) in 2017, 3.4% of high school students in the United States 
initiated sex before 13 years old (Kann et al., 2018). Approximately 9.7% of high school students 
reported having sex with more than four persons, and 28.7% reported being currently sexually 
active. Only 53.8% of those who reported being sexually active used a condom during sexual 
activity. The YRBS statistics reveal that despite the fact that many parents believe their 
adolescent children are not sexually active, a large majority of adolescents are engaging in sexual 
activity.  
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 Most parents believe their children are remaining abstinent at ages 11 to 12 years, which 
is when the HPV vaccine is recommended to be administered (Perkins et al., 2014). Parents 
voice concern about their children being too young or are convinced of their abstinence and 
therefore delay the vaccine. With the belief of a lack of necessity also comes a parental 
knowledge gap regarding the importance of vaccine initiation and completion prior to sexual 
debut. Additionally, parents have noted a reason for delaying HPV vaccination until the 
adolescent starts to become sexually active, as they believe the adolescent has a low risk for 
infection with their perceived abstinence (Moore, Fankhauser, & Hull, 2016; Zimmerman et al., 
2016). According to Mollers et al. (2015), the level of effectiveness provided by the HPV 
vaccine decreases if the adolescent has been exposed to HPV prior to vaccination. The vaccine is 
only 36% effective against persistent HPV 16 and 18 infections if there are positive HPV results 
at baseline, meaning prior HPV exposure. The vaccine is over 76% effective if there is no prior 
exposure at baseline. Adolescents ages 11 to 12 years also have a more robust immune response 
in comparison to older adolescents (Moore et al., 2016). The prior exposure rate to HPV is also 
lower at these ages; therefore, increasing vaccine effectiveness. 
Cost and Financial Concerns. In addition to concerns and beliefs regarding the 
relationship of the HPV vaccine with sexual activity, parents express concerns related to the cost 
of the vaccine. The cost of the vaccine and availability at the local healthcare office are barriers 
reported by parents (Espinosa et al., 2017). The majority of children and adolescents are covered 
by public or private health insurance, which does cover the vaccine, but this does not include all 
adolescents who are recommended to receive the HPV vaccination series (North & Niccolai, 
2016). The Vaccines For Children (VFC) program is available to cover the vaccination for 
majority of adolescents who are uninsured and meet the eligibility criteria (Oldach & Katz, 
 22 
2012). Concerns of cost occur among both parents of adolescent females and males (Javid et al., 
2016). 
Healthcare providers also note financial concerns regarding the vaccine and possible lack 
of reimbursement being a reason for decreased support and encouragement at adolescent 
appointments (Tom et al., 2016). The financial concerns for providers are system-related and 
include stocking cost and lack of insurance coverage. Depending on the VFC population, the 
perceived financial concerns are not as prominent of a barrier for providers and parents (Farmar 
et al., 2016). 
Safety Concerns. Safety concerns among parents are one of the most common barriers 
for receiving the HPV vaccine. According to Javid et al. (2016), 49% of parents of adolescent 
girls and 42% of parents of adolescent boys reported “a great deal” of concern regarding the 
safety of the HPV vaccine. An additional 31% and 30% of parents of adolescent girls and boys 
respectively expressed “somewhat” concern related to the safety of the HPV vaccine. Less than 
10% were not concerned at all about the safety of the vaccine series. 
Lack of Parental Knowledge 
 Another barrier that can interfere with HPV vaccination uptake is lack of parent 
knowledge regarding the vaccine. Several studies have evaluated parental knowledge through 
surveys and interviews (Hansen et al., 2016; Javaid et al., 2017; Oldach & Katz, 2012; Rendle & 
Leskinen, 2017; Tan & Gerbie, 2017). The lack of parental knowledge concerning the HPV 
vaccine includes a lack of knowledge about HPV infection, the vaccine series, and vaccine safety 
and efficacy information, as well as commonly believed myths. One factor that contributes to 
lack of parental knowledge of the HPV vaccine is they may not receive a recommendation or 
education about the vaccine by their healthcare providers during appointments (Javaid et al., 
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2017). Improved provider-parent communication is strongly recommended, as it can reduce this 
barrier and improve overall HPV vaccine coverage. 
 Beliefs concerning a parental lack of knowledge are voiced by nursing staff, as well as 
providers (Oldach & Katz, 2012). Lack of parental knowledge about HPV vaccines was the most 
commonly reported barrier by nursing staff and was reported to be an important barrier 55.6% of 
the time. The knowledge deficit extends to both parents of female and male adolescents. HPV 
knowledge is impacted by various sociodemographic characteristics, including gender, income, 
and race. Upon surveying U.S. adults, McBride and Singh (2018) found only 31% of males and 
28% of females believed HPV caused oral cancer. Female gender, college degree, and an annual 
income over $50,000 were all associated with increased knowledge regarding the HPV vaccine. 
 Variations in parental knowledge have also been noted between parents bringing their 
male children and adolescents to pediatric and public health clinics (Tan & Gerbie, 2017). Tan 
and Gerbie (2017) found 91% of parents at pediatric clinics versus 65% of parents at public 
health clinics were aware of HPV. Further questioning demonstrated a disparity between the two 
populations with 86% of parents at pediatric clinics knowing of the existence of the HPV vaccine 
but only 55% of parents at public health clinics. Furthermore, only 16% of pediatric clinic 
parents and 18% of public health clinic parents of boys were aware of HPV causing cancers in 
males, demonstrating a continued overall lack of HPV knowledge among parents. 
 Parental knowledge deficits are interrelated with HPV myths and concerns as well. 
Parents are unaware of accurate information and hear stories from friends or family members, 
thus influencing their level of knowledge. The amount of time a provider spends with parents 
discussing their concerns and providing education also influences overall levels of knowledge 
and can therefore impact vaccination rates and completion rates. Kornides, Fontenot, McRee, 
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Panozzo, and Gilkey (2018) discovered only 47% of parents believed the provider spent enough 
time discussing HPV and the vaccine with them and providing education. Parents who reported 
greater satisfaction with the provider encounter and time spent were far more likely to initiate the 
vaccine series. 
Lack of Provider Support 
 The awareness of provider support and recommendation for HPV vaccination is one of 
the most important and influential factors that increase HPV vaccination uptake; however, lack 
of provider support for the vaccine has been noted by parents, including provider ambivalence, 
lack of time spent discussing HPV at the visit, lack of provider knowledge, and lack of strong 
recommendation (Brown et al., 2015). Lack of provider support and recommendation is also 
linked with missed opportunities for HPV vaccination. Despite a lack of parental knowledge 
regarding HPV and the vaccine, receiving a provider’s strong recommendation for HPV 
vaccination has a positive impact on vaccine uptake and coverage and is reported to be one of the 
top five reasons for vaccination according to the CDC (McBride & Singh, 2018). 
 Provider ambivalence. Healthcare providers have a tendency to be ambivalent about 
recommending the HPV vaccine to all adolescents in the target age group, which can contribute 
to missed opportunities (Brown et al., 2015). One reason for provider ambivalence is concern 
regarding insurance coverage and cost for both the patient and clinic. Most patients should 
qualify to receive the HPV vaccine, yet not 100% will be fully covered. A second reason 
healthcare providers may not make a strong recommendation for the HPV vaccine is a lack of 
time and desire to explain why males should also receive the vaccine (Oldach & Katz, 2012). 
Many parents of males require additional time and education concerning the need for male HPV 
vaccination. Providers can be dissuaded by the additional needs and complexity of the situation. 
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Oldach and Katz (2012) further discuss how parents then may interpret a lack of education and 
time spent discussing the importance of male vaccination as a reason to delay or refuse 
vaccination, believing in a decreased risk for males. 
 Provider beliefs about parental perceptions of HPV vaccination and an overestimation of 
parental concerns about safety also contribute to provider ambivalence (Clark et al., 2016). 
Providers may misinterpret the safety concerns of parents and feel that they are unable to change 
parents’ minds about vaccination. Therefore, they may not discuss the HPV vaccination in detail. 
Misinterpretation and misinformation can manifest as provider uncertainty about the importance 
of HPV vaccination and further dissuade parents and adolescents of the importance. 
 Lack of time. Numerous studies have shown a lack of time with the patient impacts the 
amount of support parents perceive healthcare providers to have with HPV vaccination (Brown 
et al., 2015; Gowda et al., 2012; Kornides et al., 2018). Many adolescent healthcare visits are 30 
minutes or less, placing a time constraint on the appointment (Brown et al., 2015). The shortened 
visit impacts the amount of time providers are able to spend providing education about the 
importance of HPV vaccination. As with provider ambivalence, the time constraint causes 
providers to have to rush or feel pressured about the educational topics stressed during the visit, 
causing uncertainty for both patients and parents about vaccine importance. 
 Gowda et al. (2012) discovered providers generally recognize the importance of 
discussing the vaccine, safety, and efficacy with parents and adolescents; however, the amount of 
time required to effectively educate does not exist during most visits. Many of the parental 
concerns voiced take time to comprehensively discuss. Parental satisfaction with providers and 
initiation of HPV vaccination is linked with a belief that the correct amount of time was spent 
during the visit discussing HPV (Kornides et al., 2018). The more time spent discussing the 
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importance, safety, and efficacy of HPV vaccination is directly linked with improved vaccination 
acceptance, yet providers express a lack of available time for this. 
 Lack of provider knowledge. A third factor that may interfere with HPV vaccination 
uptake is a lack of provider knowledge and information. A survey of providers done by Tom et 
al. (2016) revealed around 80% of providers have good knowledge about HPV; however, nearly 
17% were unsure of any connection between HPV and head and neck cancer. Additionally, 
healthcare providers were also unsure of when HPV is most commonly found and if it can be 
cleared without any treatment. The results demonstrate a lack of provider knowledge and a level 
of uncertainty. On the other hand, vaccine knowledge scores were higher with over 94% of 
providers answering correctly. Ultimately, an overall lack of provider knowledge regarding HPV 
may contribute to reduced HPV acceptance rates among parents and adolescents.  
 Lack of strong recommendation. Another factor that may be a barrier to HPV 
vaccination is lack of a strong recommendation for the vaccine by healthcare providers. 
Receiving a provider’s recommendation for HPV vaccination has been found to be critical for 
vaccination uptake and coverage (Hansen et al., 2016). Unfortunately, provider ambivalence and 
a lack of time can interfere with healthcare providers’ ability to make a strong recommendation 
for vaccination. Therefore, a lack of provider recommendation continues to be a fundamental 
barrier (Farmar et al., 2016). 
 A majority of providers report supporting HPV vaccination fully; however, the approach 
to recommendation and advocating for HPV vaccination varies greatly (Javaid et al., 2017). 
Approximately 57% of providers use a bundling approach and list the HPV vaccine between the 
additional adolescent vaccinations, while 29% of providers explain the HPV vaccine as being an 
optional vaccine and set it apart from other adolescent vaccinations. The manner of presenting 
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the HPV vaccine is believed to impact the strength of the recommendation. Offering the vaccine 
as optional may contribute to not effectively advocating for the vaccine. Javaid et al. (2017) 
found that 69% of healthcare providers feel a lack of provider recommendation impacts HPV 
vaccine uptake for girls “a great deal.” 
 Receiving a provider recommendation at every adolescent visit demonstrates the 
importance of HPV vaccination and can increase initiation and completion rates (Zimmerman et 
al., 2016). The recommendation for initiation and completion of vaccination should be strong 
and clear as to not cause parental uncertainty (Brown et al., 2015). Krantz et al. (2017) found a 
direct correlation between the level of provider recommendation and missed vaccination 
opportunities with a higher number of missed opportunities occurring with weaker 
recommendations. Between 35% and 58% of families were unable to recall any sort of provider 
recommendation for HPV vaccination. 
 Moore et al. (2016) noted parents will commonly follow a healthcare provider’s 
recommendations, including those for HPV vaccination, when they believe the recommendation 
is strong. A strong recommendation consists of a clear and straightforward message for parents. 
The ambivalence of the message and recommendation from the provider can be perceived to 
decrease its strength and significance (Kulczycki, Qu, & Shewchuk, 2016). A lack of strength in 
the provider recommendation or lack of recommendation overall are linked with a negative 
impact on HPV vaccination rates. Provider recommendation for HPV vaccination is key as 
parental HPV awareness and understanding without recommendation do not automatically result 
in HPV vaccination (Pierre-Victor et al., 2017a). 
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Missed Opportunities 
 As previously defined, missed opportunities are adolescent visits when HPV vaccination 
is not provided but TDaP and MenACWY are administered and may include well-child 
adolescent visits or any visit with the primary care provider in which the HPV vaccination was 
due but not administered (Espinosa et al., 2017). Missed opportunities were commonly seen at 
well-child visits and vaccine-related visits. Espinosa et al. (2017) found the HPV vaccine was 
given 37% of the time with other adolescent vaccines, demonstrating a missed opportunity 
occurs more than 60% of the time. Pediatricians were noted to have lower rates of missed 
opportunities in comparison to non-pediatricians, which may contribute to lower HPV 
vaccination rates in more rural settings where pediatricians may not be readily available. 
Although HPV vaccination coverage has made progress, the progress is limited with coverage 
rates significantly lower than those for TDaP and MenACWY (Reagan-Steiner et al., 2016). The 
comparison of coverage between the recommended adolescent vaccinations demonstrates 
continued missed opportunities specifically for the HPV vaccination itself. 
 Brown et al. (2015) discuss the significance of missed opportunities at problem-focused 
visits. Over 90% of problem-focused adolescent visits, including visits while adolescents were ill 
or seen for medication changes, were missed opportunities for HPV vaccination. In order to 
continue to improve vaccination coverage, every visit with adolescents should be viewed as an 
opportunity to provide education and HPV vaccination (Farmar et al., 2016). The frequency and 
strength of the provider education and recommendation provided at the visits has the potential to 
increase vaccination coverage (Krantz et al., 2017). Sussman et al. (2015) interviewed primary 
care providers and found it common for them to struggle with advocating for vaccination at 
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every visit, especially the acute care visits. The providers noted this struggle as a contributing 
factor for a missed opportunity for HPV vaccination. 
 Missed opportunities also arise when parents and adolescents are not provided the 
education about the vaccination series recommendations and the need for additional 
appointments and follow-up (Moore et al., 2016). Missed opportunities are reported to be the 
most common reason for the significantly lower HPV vaccination rates in the United States 
(Javaid et al., 2017). Providers may not be aware of the current impact of missed opportunities or 
do not have the skills to reduce them. Additional education and communication skills are needed 
for healthcare providers to reduce the number of missed opportunities and positively impact 
HPV vaccination coverage. 
 Provider-parent communication may also contribute to missed opportunities. Provider 
beliefs about parental concerns and the lack of additional time required to discuss HPV 
vaccination in detail may cause delay of discussion and therefore vaccination (Clark et al., 2016). 
The barrier of HPV myths also becomes a factor in missed opportunities. The myths about the 
risk for increased sexual activity and timing of vaccination are linked with both parent and 
provider delay for the recommendation of the HPV vaccine (Perkins et al., 2014). Conversational 
awkwardness for providers, parents, and adolescents is also a factor for a delay in conversation 
and subsequent missed opportunities (Daley, 2011). 
Lack of Follow-Up 
 Lack of follow-up for HPV vaccination for the completion of the two or three-dose series 
also contributes to lower HPV completion rates. Missed opportunities to provide education to 
adolescents at each visit cause decreased awareness of the significance of series completion, 
which may contribute to lower rates of follow-up (Zimmerman et al., 2016). Provider 
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ambivalence and lack of recommendation and support also contribute to a lack of follow-up due 
to parental perceptions (Brown et al., 2015). 
Improving HPV Immunization Acceptance 
Communication Strategies 
 With research demonstrating multiple barriers for improved HPV vaccination coverage, it 
is essential to evaluate the possible solutions that can reduce the barriers and increase coverage. 
Provider-parent communication is a vital component during adolescent visits. Communication 
consists of the education provided, as well as recommendations for vaccination. Research has 
found several successful communication strategies for improving HPV vaccination rates, 
including framing, normalizing, bundling, providing a clear recommendation, implementing 
provider-initiated discussion, and using presumptive communication (CDC, 2018g; Opel et al., 
2013; Perkins et al., 2014). 
Framing. Framing is the manner in which the provider discusses the HPV vaccine and 
how it is compared to the other recommended adolescent vaccinations. The HPV vaccine is 
sometimes listed separately from other recommended or required adolescent vaccinations 
(Gilkey & McRee, 2016). Higher levels of parental hesitancy are associated with using an 
optional approach of HPV vaccination. Parents may also interpret the message and 
recommendations as being weaker when the vaccination is framed in an optional way, causing it 
to sound less important (Gilkey et al., 2016). 
Additionally, framing is used when providing education specifically about HPV 
vaccination. Gain-framing and loss-framing are two techniques available to providers to use 
(Gilkey & McRee, 2016). Gain-framing focuses on the positive effects, while loss-framing 
focuses on the negative consequences associated with lack of action, such as HPV vaccination 
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(Lee & Cho, 2017). Loss-framed messages tend to be more effective on influencing vaccination 
behavior and willingness. 
Bundling. Bundling is a communication technique in which the HPV vaccine is 
sandwiched between TDaP and MenACWY (Espinosa et al., 2017). The three recommended 
adolescent vaccines are grouped together instead of HPV being listed as optional. Bundling 
corresponds with the provider’s framing method. This is a successful technique according to 
research by Farmar et al. (2016). The use of bundling the HPV vaccination with other required 
vaccinations is supported by the CDC (CDC, 2018g). CDC provider resources and handouts 
contain the recommendation to bundle adolescent vaccinations, including the HPV vaccine, to 
improve coverage rates. 
Normalizing. A third successful communication strategy for providers to use during 
parent and adolescent HPV vaccination conversations is to normalize the HPV vaccine. 
Normalizing is done by not singling the vaccine out as distinctly separate from the other 
vaccinations (Perkins et al., 2014). Normalizing causes the HPV vaccine to appear to be of equal 
importance to parents when compared to TDaP and MenACWY. The concept of normalizing 
HPV vaccination is demonstrated when using a bundling approach to vaccination discussion 
(Espinosa et al., 2017). 
Providing a clear recommendation. According to the CDC (2018g), the number one 
reason for HPV vaccination is attributed to a strong provider recommendation. The concept is 
simple, yet still a significant barrier as previously discussed. Providing education about HPV and 
the complications is not enough to cause vaccine initiation and series completion (Pierre Joseph 
et al., 2016; Pierre-Victor et al., 2017b). HPV knowledge alone does not cause increased HPV 
vaccination rates. Knowledge plus a healthcare professional’s recommendation together make a 
 32 
difference. It is important for providers to consistently recommend HPV vaccination and view 
every visit as an opportunity to vaccinate and educate (Farmar et al., 2016). Consistent 
recommendations are believed to be stronger recommendations and are therefore followed more 
often. Providing a clear and strong recommendation for HPV vaccination is a successful 
communication technique. 
The strength of a recommendation is influenced by the framing used, education provided 
following the recommendation, and the clarity of the recommendation. Pierre-Victor et al. 
(2017a) found providers should focus on the HPV vaccine being used for cancer prevention, 
providing a clear message about the benefits of receiving the vaccine. The provider 
recommendation also must be clear about when the vaccine is to be given (Kornides et al., 2018). 
A strong recommendation advocates for same day administration. 
Provider initiated discussion. Failure to communicate with parents and discuss HPV 
vaccination is linked with a lack of series initiation and completion (Kulczycki et al., 2016). 
Providers are encouraged to initiate the conversation by recommending the vaccination and then 
further discussing the indication, safety, and efficacy. Kulczycki et al. (2016) found that 
providers who initiated the conversation regarding HPV vaccination and perceived minimal 
barriers to dialogue had better coverage rates for both initiation and continuation of HPV 
vaccination. Discussion is to continue at every visit, which correlates to strong provider 
recommendations and parents staying informed. 
Using presumptive communication. Presumptive communication is a technique in 
which the result is presupposed in the statement and can be used to frame and recommend HPV 
vaccination (Opel et al., 2013). Presumptive HPV vaccination states in the recommendation that 
the vaccination will be given at the visit with the other recommended vaccinations. Presumptive 
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communication is recommended to be used instead of participatory communication, which is 
more open-ended and allows for a greater amount of parental input and decision-making. 
Participatory communication questions whether or not HPV vaccination will be provided at the 
visit and is associated with a perceived weaker recommendation for HPV vaccination. 
Participatory communication strategies are linked with higher amounts of parental hesitancy and 
resistance. 
 Opel et al. (2013) discovered it is common for providers to use participatory 
communication with known vaccine hesitant parents in comparison to known non-vaccine 
hesitant parents. Approximately 83% of the sampled population expressed greater resistance to 
vaccination when participatory vaccination communication was used in comparison to 26% with 
presumptive vaccination communication. Additionally, Opel et al. (2013) noted if providers 
continue to pursue the topic of vaccination after encountering parental resistance, roughly half of 
parents will change their minds and opt to have children receive the recommended vaccinations. 
Presumptive communication and continued recommendations, even after resistance, are positive 
and successful communication techniques. 
Appointment Scheduling 
 Scheduling follow-up appointments for adolescents or bundling HPV vaccination with 
other follow-up visits is one solution to improve the known barrier of a lack of follow-up for 
HPV vaccination alone (Simons et al., 2015). Conflicting expectations between parents and 
healthcare providers about who is the responsible party for ensuring series completion exist 
(Sussman et al., 2015). Sussman et al. (2015) found that 65% of parents expect the clinic to 
remind parents and adolescents about scheduling and completing the vaccine series; however, 
52% of providers reported it is their responsibility to explain the HPV vaccination schedule but 
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the parents’ responsibility to make the appointments. Improved vaccination rates and series 
completion rates are seen with scheduled appointments (Williams et al., 2017). 
Education 
 Healthcare professionals’ education provided to parents and adolescents is a critical piece 
of HPV vaccination uptake in addition to the recommendation for vaccination. Kulczycki et al. 
(2016) found that provers who discuss HPV vaccination in addition to providing a 
recommendation have higher rates of vaccination administration than those who do not. The 
focus of the education should be on the cancer prevention aspects of the HPV vaccination and 
not the route of HPV transmission (Pierre-Victor et al., 2017a). The framing of the education 
provided to parents and adolescents has a strong impact on their perception of the vaccine. 
Educational focus on STI prevention in comparison to cancer prevention is not as beneficial. STI 
prevention focused education typically has a negative impact on HPV vaccination initiation. 
Pierre-Victor et al. (2017b) recommend providers prioritize HPV recommendation and education 
efforts in order to improve vaccination coverage. Cancer prevention focus and framing are key 
when providing education (Espinosa et al., 2017). 
Theoretical Framework 
 In order to properly implement a performance improvement project and conduct 
evidence-based practice (EBP), it is essential to use both a theory and a model for project 
development. Both the theory and model guide project development and encourage the success 
of project implementation. A theory for practice and model are essential factors utilized in this 
project to create an educational intervention for healthcare providers. 
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Theory for Practice 
 In 1968, Malcolm Knowles developed an adult learning theory known as andragogy 
(Merriam, 2001). Andragogy was created to better explain how adults learn in comparison to 
children and the distinct differences between the two. The definition of andragogy is “the art and 
science of helping adults learn” (Daily & Landis, 2014, p.2066). Adult learning theory is 
pertinent to the proposed performance improvement project because the project incorporates 
providing education specifically to adult healthcare workers. In order to provide the most 
appropriate forms of education, it is important to apply a theory created to explain how adults 
learn best.  
 Knowles identified five key assumptions within adult learning theory. The first 
assumption is that each adult uses self-directed learning and has an independent self-concept 
(Merriam, 2001). In comparison, children are dependent learners and must rely on other to teach 
them. Daily and Landis (2014) further explain the self-concept of learning for healthcare 
providers as a professional responsibility. Healthcare providers must take time after their 
education is complete to continue to learn and grow with the ever-changing healthcare industry. 
The performance improvement project provides an educational session about the HPV vaccine 
and communication strategies for providers to use to improve HPV vaccination coverage and 
reduce missed opportunities. Various educational resources and communication strategies were 
included for the healthcare providers to take away and review further. The project also offered 
healthcare professionals the opportunity to further self-direct their learning and future 
implementation of new communication techniques for parent-provider HPV vaccination 
discussions. 
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 The second assumption is that adults accumulate an abundance of knowledge through 
their life experiences and can use the knowledge as a resource to further their learning (Merriam, 
2001; Daily & Landis, 2014). Adults are able to look back on their experiences and use this 
knowledge to determine future decisions. Example scenarios were included in the educational 
presentation to allow for providers to draw on their past experiences and knowledge to determine 
their actions and responses. Each provider has a unique reservoir of knowledge and therefore, 
was able to provide unique feedback to others, as well as about the possible outcomes for each 
situation and how to improve the outcome to result in HPV vaccination. 
 Knowles’ third assumption explains how the learning needs of adults are dependent upon 
social roles and any changes occurring (Merriam, 2001). Adults are goal-oriented learners and 
have a readiness to learn in relation to developmental tasks and social roles (Cercone, 2008). In 
order to apply Knowles’ third assumption within the educational project, the objectives were 
presented at the beginning of the presentation and were targeted towards HPV vaccination 
missed opportunities and communication strategies. The reason for learning the new strategies 
was emphasized throughout the presentation and specifically highlighted at the beginning for 
providers to understand the project’s impact on their specific learning goals. 
 The forth assumption of andragogy factors in the change in perspective that occurs with 
maturation (Cercone, 2008). As adults age, their reason for learning and focus change from 
concerns for future application to the immediacy of application. The change from future 
application to immediacy of application encompasses the adult’s reason for why they need to 
learn the new information and why it is important to them. A brief focus on the current HPV 
vaccination statistics, as well as current barriers, assisted the healthcare professionals to better 
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understand why the presented information was important and necessary to learn. The participants 
were able to implement the communication strategies immediately into their practice. 
 The fifth and final assumption of Knowles’ adult learning theory is that adults are 
motivated to learn through internal factors, such as self-esteem and job satisfaction, instead of 
external factors (Cercone, 2008). The project evaluated each providers’ HPV vaccination 
statistics prior to and after the educational intervention by accessing aggregate data from the 
EHR. The results may have influenced job satisfaction and improved healthcare professional’s 
self-esteem. Improved knowledge and resources for HPV vaccination, as well as parent-provider 
communication, may also have increased self-esteem. Additionally, each provider’s experience 
with HPV vaccination was respected during the presentation with feedback provided in a 
constructive and respectful manner. The post-test survey done at the end of the education session 
included a space for self-reflection and feedback for improvement as well. 
 With creation and implementation of the HPV vaccination educational presentation, the 
assumptions of andragogy were incorporated. Objectives, provider needs, and goals were equally 
integrated throughout the project (Daily & Landis, 2014). The theory is learner-centered and 
emphasizes the importance of feedback for both the learners and educators (Taylor & Hamdy, 
2013). Consistent and constructive feedback are essential for provider learning and project 
success. 
Model 
 The use of a model to guide a performance improvement project and practice change is 
fundamental (Melnyk & Fineout-Overholt, 2015). For the purpose of the HPV vaccination 
performance improvement project, the Promoting Action on Research Implementation in Health 
Services (PARIHS) framework was used. The PARIHS framework was developed originally in 
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1998 and then adapted over time to the current version in 2004. It was created from an 
examination of practice development, quality improvement, and research. The framework guided 
implementation and sustainability for the evidence-based project. The model fit seamlessly 
because it demonstrated the various interdependent relationships and intricacies of factors within 
a performance improvement project. 
 The model consists of three main elements: evidence, context, and facilitation (Melnyk & 
Fineout-Overholt, 2015). Each of the three main elements consist of subelements. The 
subelements for each section are explained by examples of low and high characteristics to guide 
implementation and sustainability. The first element to consider is evidence. Evidence is a 
comprehensive sense of the knowledge found within the framework and project itself. The 
knowledge is both real and academic. There are four subelements: research, clinical experience, 
patient experience, and local data. The subelements of evidence are used to guide the review of 
literature regarding the topic of HPV vaccination and were used throughout the project during 
the educational sessions. All of the subelements of evidence have a high level of value within the 
framework and project. Thorough research of HPV vaccination and communication strategies 
was necessary for a comprehensive level of knowledge. The research also included patient 
experiences with an emphasis on parental opinions and beliefs about HPV vaccination and 
interactions with providers. Local data regarding current HPV vaccination coverage rates in 
comparison to national rates were additional key pieces of evidence within the project. The 
clinical experience subelement corresponded nicely with the adult learning theory as well 
because it allowed the providers to draw on their wealth of knowledge and experiences to further 
their learning. 
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 The second element is context, which consists of culture, leadership, and evaluation 
(Melnyk & Fineout-Overholt, 2015). The project focused on promoting learning within the 
organization by including both providers and nursing staff at the educational session. The culture 
subelement was also used through ensuring the project implemented staff values and the culture 
of caring found at the facility. Improving HPV immunization coverage and decreasing associated 
cancer rates fits with the HealthyPeople 2020 goal for HPV vaccination coverage of >80% and is 
a key practice issue. The subelement of leadership is integrated teamwork, and this was achieved 
during the project by having both nursing staff and providers present for the education and 
receiving input from past experiences from everyone in attendance. Clear roles and an 
empowering approach to teaching the session and future impact were also be used. The 
evaluation of the project occurred throughout the project with feedback during the education 
presentation about past experiences and sample scenarios, as well as at the end on a post-test. 
Additional evaluation of any changes in HPV vaccination rates was also performed to better 
understand the impact of the project and any needed changes in the future. 
 The final element of facilitation consists of two subelements: purpose role and skills and 
attributes (Melnyk & Fineout-Overholt, 2015). The purpose role for the HPV vaccination project 
was to enable others to improve their practice through adult learning methods of education and a 
holistic approach involving both providers and nursing staff. The skills and attributes subelement 
varied depending upon the stage of implementation and the roles involved. The facilitation 
element helped to create sustainability and better implementation of the evidence-based 
recommendations for HPV vaccination practice and communication changes. 
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Conclusion 
 In conclusion, persistent HPV infection is linked with several serious complications, 
including anogenital and oropharyngeal cancers (CDC, 2016a). The HPV vaccine has been 
approved by the FDA since 2006 and available to reduce the rates of HPV and the complications. 
Despite the vaccines’ existence, HPV vaccination coverage rates remain below the Healthy 
People 2020 goal of greater than 80%. Several barriers of vaccination coverage have been 
identified, including lack of parental knowledge, lack of provider support, and missed 
opportunities. Options exist to reduce the barriers and enhance HPV vaccination uptake. 
Interventions for healthcare professionals are needed to provide knowledge about the current 
problem with low HPV vaccination coverage and methods to enhance knowledge and 
communication strategies. 
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CHAPTER 3. PROJECT DESCRIPTION 
Congruence with the Organization’s Strategic Plan 
 The practice improvement project was created in congruence with the strategic plan 
developed by the College of Health Professionals at North Dakota State University (NDSU). One 
approach included within the strategic plan was to improve relationships with outside 
organizations and partnerships to support research (NDSU, 2017). The project required 
partnership with a local healthcare facility, Sanford Health. A meeting with Sanford Health was 
held in the Spring of 2018 and permission was granted for the project to be done at two rural 
clinics in Jamestown, North Dakota and Valley City, North Dakota. All parties involved in the 
research relationship were supportive of the project and the potential to improve current HPV 
vaccination knowledge. A follow-up meeting is planned to discuss the results of the practice 
improvement project and the implications for future research, including options to increase 
sustainability. Additionally, NDSU Institutional Review Board (IRB) approval was received on 
October 4, 2018. Please see Appendix A for further information. 
 The second strategic plan aspect incorporated within the practice improvement project 
was a goal for “health professions training, research, and service activities of the College support 
the needs of North Dakota” (NDSU, 2017, p.7). The research and health professions training in 
this project was North Dakota-based. The current HPV vaccination coverage rate for receiving 
≥1 dose for male and female adolescents age 13-17 in North Dakota was 67.7%; however, this 
rate was still significantly below the Healthy People 2020 goal of greater than 80% (CDC, 
2018b). HPV vaccination coverage demonstrates an area of need in North Dakota. One objective 
within the project focused on reducing the number of missed vaccination opportunities, which 
may help improve coverage rates. 
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 Finally, the project corresponded with the goal of improved professionalism and 
increased interprofessional education (NDSU, 2017). The practice improvement project involved 
several members of the healthcare team including medical doctors, nurse practitioners, and 
nurses. The educational intervention was provided to the entire group together with encouraged 
discussion among all parties in attendance. Interprofessional relations were also promoted within 
the clinical dissertation committee. The committee was formed with members from nursing, 
biological sciences, and community healthcare. 
Project Objectives 
 Healthcare professionals are key to improving HPV vaccination coverage. The 
professionals must be aware of the current data, barriers for vaccination coverage, their role, 
missed opportunities, and strategies for improvement in order to influence positive change and 
increased HPV vaccination coverage. A clinic education program was developed for the purpose 
of achieving the project objectives, which included the following: 1) to improve the healthcare 
professionals’ level of knowledge of the HPV vaccine, safety, and efficacy, 2) to reduce the 
number of missed opportunities of HPV vaccination at the clinics, and 3) to improve the level of 
healthcare professionals’ comfort in the communication strategies used to improve HPV 
vaccination coverage rates. 
Project Design 
 The practice improvement project was an evidence-based educational intervention, which 
was built on results from numerous research studies revealing the need for further provider 
education and interventions to reduce the number of missed HPV vaccination opportunities and 
improve HPV vaccination coverage rates (Farmar et al., 2016). Healthcare professionals’ level of 
knowledge and strong recommendation for HPV vaccination are key factors in adolescent HPV 
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vaccination coverage (Hansen et al., 2016). Parents rely on the knowledge and beliefs of the 
healthcare professionals (Kornides et al., 2018). The more satisfied parents are with the 
recommendation and education they received from the professionals, the more likely they are to 
agree to adolescent HPV vaccination. 
 Healthcare professionals face several barriers when trying to improve HPV vaccination 
coverage, including a lack of parental knowledge, HPV myths, and a lack of provider support 
leading to missed opportunities (Brown, Hopfer, & Chan, 2015; Tom et al., 2015). Strategies to 
reduce the amount of provider barriers and reduce the overall barriers for HPV vaccination exist. 
The focus of the practice improvement project was the various available strategies for 
improvement, including communication strategies, scheduling HPV vaccination appointments 
for series completion, and the importance of the healthcare professionals’ recommendation. 
Additional information included for enhanced understanding of the topic of HPV vaccination 
was as follows: background on HPV infection and the related complications, the HPV vaccine, 
current coverage rates, barriers for HPV vaccination, and missed opportunities. Research has 
demonstrated improved HPV vaccination coverage after the successful implementation of an 
educational intervention for healthcare professionals (McLean et al., 2017). 
 The education was provided in a 50 to 60-minute presentation. The presentation was held 
three times in Jamestown and one time in Valley City due to clinic size and the patient 
populations. The third presentation in Jamestown was during the weekly provider meeting per 
the request of the physician director. The presentation was shortened to a condensed version per 
manager request during the meeting to allow for the necessary information to be provided in a 
timely manner. The condensed presentation was 30 minutes in length due to time constraints and 
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covered the same topics with more emphasis placed on the communication strategies and 
methods to reduce missed opportunities for HPV vaccination.  
Additional examples including framing of the HPV vaccine and addressing parental 
concerns were presented during the educational intervention. Training in communication 
strategies and patient education is recommended by research to potentially reduce the number of 
missed opportunities and increase vaccination uptake (Javaid et al., 2017). Decreasing the 
number of missed opportunities and HPV vaccination coverage improvement should encompass 
provider training and education (Brown et al., 2015). Healthcare provider educational sessions 
have been shown to improve coverage rates, with an added benefit of recurrent educational 
opportunities for sustainability (Krantz et al., 2017). 
 The educational information was presented using a PowerPoint format with handouts 
provided for further review. Please see Appendix B and Appendix C for the educational 
presentation and condensed presentation format. Visual data was encompassed within the 
presentation, including graphs and coverage maps. Training videos from the Center for Disease 
Control and Prevention were shown during the presentation. The training videos discussed 
sample scenarios for presenting HPV vaccination using the communication strategies examined. 
One training video also discussed the topic of parental refusal and an evidence-based approach to 
address the situation. Please see Appendix D for the transcription of the training videos. After 
completing the educational seminar, the participants were given a post-test questionnaire to 
complete. A section for feedback was also available at the end of the post-test questionnaire. 
Please see Appendix F for the post-test questionnaire.  
 Data regarding missed opportunities for HPV vaccination and clinic HPV vaccine 
statistics were collected. A retrospective analysis for 2 months prior to project implementation 
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and for 2 months after implementation was done to allow for comparison. The HPV vaccination 
statistics were compared with those on the county and state level. Additional statistical data 
collected included common primary diagnoses for missed opportunity visits and patient gender. 
Resources 
 Several various resources were utilized throughout the planning, implementation, and 
evaluation of the practice improvement project. Technology, time commitments, and personnel 
were required for the successful completion of the project. The personnel include the members of 
the clinical dissertation committee that was formed and a contact person at Sanford Health. The 
committee members had a variety of backgrounds and offered unique expertise. The investigator 
and clinical dissertation committee were required to spend a significant amount of time 
researching, planning, implementing, and evaluating the educational intervention. All healthcare 
professionals who agreed to participate in the proposed project were also required to spend 
approximately 60 minutes of their time completing the educational seminar and post-test 
questionnaire. 
 The technology used for the purpose of the project was essential for its successful 
completion. PowerPoint was vital for the educational seminar, as well as the presentation of the 
final project and results. Technology was used to assess data and determine the results of the 
project. The data assessed include responses to the post-test questionnaires and clinic statistics of 
missed opportunities and HPV vaccines given during the proposed time frame. Sanford Health 
technology support, nurse managers, and vaccine champions aided in the collection of 
vaccination and missed opportunity data. 
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Protection of Human Subjects 
 The human subjects who were involved in the project were healthcare professionals only. 
There was no direct patient contact during the project. The healthcare professionals did include 
women and minorities; however, no children were included in the practice improvement project. 
The statistics obtained were in an aggregate format with no personal identifiers included. 
 Protection of the human subjects involved in the study was ensured by the North Dakota 
State University Institutional Review Board. The project was reviewed and approved by the 
board and by school administration on October 4, 2018. Approval was obtained from Sanford 
Health through a proposal process on February 28, 2018. Participants were recruited through 
facility emails, flyers, and word of mouth communication. Please see Appendix E for the 
invitation e-mail that was sent to health professionals. Voluntary informed consent was obtained 
prior to the start of the education seminar with verbal permission from participants received. 
Healthcare professionals in attendance were reminded the project was voluntary, and personal 
information was kept confidential. Treats and refreshments were offered during each of the 
educational presentations. As an added incentive, a drawing for a $10 gift card was done at the 
sessions for those who attended. 
 The project had several benefits. The benefits included the knowledge gained by 
healthcare providers regarding HPV, the HPV vaccine, current barriers for vaccination, missed 
opportunities, and strategies to enhance vaccination uptake. However, the project did not reduce 
the number of missed opportunities or increase HPV vaccination coverage. Healthcare 
professionals also gained increased levels of comfort with new communication techniques and 
strategies for HPV vaccination improvement. New communication techniques for providers are 
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essential, as parents’ level of satisfaction with the healthcare provider’s recommendation for 
HPV vaccination can influence vaccination behavior and coverage (Kornides et al., 2018). 
 The knowledge gained through the project is critical because it can impact future 
healthcare professionals’ practice and patient interactions. The knowledge gained also has the 
potential to reduce the number of missed opportunities and improve HPV vaccination coverage. 
Improved vaccination coverage will impact future rates of HPV infections and related 
complications. The knowledge can also impact future research regarding the impact of a 
healthcare professional educational intervention, as well as methods to improve vaccination 
coverage and reduced missed opportunities. A meeting will be held with Sanford Health to 
discuss the results of the practice improvement project, along with possible plans for 
sustainability. Potential plans for sustainability include the use of an online learning module or 
Sanford Learn and quarterly staff questions. 
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CHAPTER 4. EVALUATION 
Evaluation Methods 
Two forms of evaluation were used for the practice improvement project. The first was a 
post-test questionnaire. The post-test questionnaires were used to gain a better understanding of 
the healthcare professionals’ level of HPV knowledge, as well as level of comfort with new 
communication strategies and methods for HPV vaccination coverage improvement. 
Questionnaires provide valuable information and have been used to collect data regarding 
provider knowledge about HPV (Kulczycki et al., 2016). Roussos-Ross, Foster, Peterson, and 
Decesare (2017) reported an increase in vaccine knowledge using a post-seminar survey to 
evaluate participants after an educational intervention. The post-test questionnaire incorporated 
the PARIHS framework by including clinical experience demographic information and 
questions. The demographic data collected, including current position and years of practice, was 
used to determine level of clinical experience for each of the participants. The post-test questions 
were designed to evaluate project objectives one and three using evidence-based information 
gathered during the literature review and presented during the educational session. Two or more 
questions were created per objective.  
The second form of evaluation was the statistical data regarding the number of HPV 
vaccinations administered at each clinic two months prior to the educational session and two 
months after the session. The number of missed opportunities from each facility during the same 
time frame was also collected. The literature supports the effectiveness of education sessions in 
reducing missed HPV opportunities, as Javaid et al. (2017) noted how targeted interventions 
could be used to reduce the number of missed opportunities for HPV vaccination. Additionally, 
provider and staff education has been shown to impact HPV vaccination uptake (McLean et al., 
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2017). The statistical data was used to evaluate objective two. Aggregate data was obtained as 
per the IRB approval. The statistical data aligned with the subelement of local data from the 
PARIHS framework. 
Objective One 
The first project objective was to improve healthcare professionals’ level of 
understanding and knowledge of the HPV vaccine, safety, and efficacy. Approximately one-third 
of the education materials and PowerPoint presentation, both original and condensed format, 
focused on objective one. Four post-test questions were used to evaluate the presentation and 
assess if the objective was met. The first question was as follows: “For both males and females 
ages 9-14 years, what is the correct HPV vaccine dose regimen?” Response options were: a) 2-
dose regimen: now and three months, b) 2-dose regimen: now and six months, c) 3-dose 
regimen: now, one-two months, and six months, d) 3-dose regimen: now, one month, and three 
months. The second question was as follows: “The HPV vaccine is associated with which of the 
following adverse events (select all that apply).” The response options were: a) venous 
thromboembolism (VTE), b) neurologic events, c) autoimmune events, d) localized injection site 
pain, e) none of the above. The third post-test question evaluating objective one was as follows: 
“The nine-valent HPV vaccine has demonstrated _____ efficacy if given prior to the initiation of 
sexual activity.” The responses were: a) 92%, b) 87%, c) 96%, d) 78%. The final question was as 
follows: “Which of the following has been found to be the most significant factor in determining 
HPV vaccine acceptance and initiation among parents and adolescents?” The response options 
were: a) provider recommendation, b) amount of education provided, c) increased time for 
appointment, d) advertisement recommendation. Please see Table 1 for further information.   
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Objective Two 
The second project and learning objective was to reduce the number of missed 
opportunities for HPV vaccination at each of the facilities. Statistical data was used to evaluate 
the project and verify if the objective was met post-implementation. The statistical data included 
the number of missed opportunities at both the Sanford Health clinics in Jamestown and Valley 
City. The missed opportunity data originally looked at children and adolescents ages 11-17 years 
but was later expanded to ages 11-4 years and 15-26 years due to the data received from Sanford 
Health. Missed HPV opportunities were compared to missed opportunities for the other 
adolescent vaccines as well. The reason for the patient visit when the vaccine was missed was 
also included in the data. Additional statistical data used to evaluate the project objective were 
the total number of HPV vaccines given during the project time and HPV up-to-date rates for 
patients ages 11-14 and 15-26. The total number of adolescent visits were calculated for each 
month. The Sanford Health immunization strategy leader collected and supplied the aggregate 
data for the objective, as well as the project coordinator for the Department of Public Health. 
Objective Three 
The third objective was to improve healthcare professionals’ level of comfort in 
communication strategies that can be used to improve HPV vaccination coverage rates. The 
objective was evaluated with two post-test questions. The two questions used a Likert scale to 
assess healthcare professionals’ opinions. The first questions was as follows: “Following the 
education presentation, I have an increased understanding of HPV, the HPV vaccine, and 
communication strategies used to reduce missed opportunities and improve vaccine coverage.” 
The response options included: 1) strongly disagree, 2) disagree, 3) neutral, 4) agree, 5) strongly 
agree. The second questions was as follows: “Following the educational presentation, I am more 
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comfortable discussing HPV and the HPV vaccine with parents and adolescents.” The response 
options were the same for the second statement as the first. Additionally, the post-test included a 
section for comments and feedback regarding the presentation and educational information 
provided. Please see Table 1 for additional information. 
 Several participants reported positive feedback after attending the educational 
intervention. Feedback and comments during the educational intervention included discussing 
the current HPV-positive cervical cancer rates in Australia and the impact of their vaccination 
program. One comment provided in the comments section stated, “Good job!” Other staff stated 
they found the information very helpful and planned to use it later the same day. Additional staff 
who were unable to attend requested to know if more opportunities would be available because 
of what they were hearing from participants. 
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Table 1 
Practice Improvement Project Objectives and Assessment Questions 
Question Response Options Method of 
Instruction 
Length of 
Instruction 
Objective 1: Improve healthcare professionals’ level of knowledge of the HPV vaccine, 
safety, and efficacy 
For both males and 
females ages 9-14 
years, what is the 
correct HPV vaccine 
dose regimen? 
a) 2 dose-regimen: 
now & 3 months 
b) 2-dose regimen: 
now & 6 months 
c) 3-dose regimen: 
now, 1-2 months, 
& 6 months 
d) 3-dose regimen: 
now, 1 month, & 
3 months 
Lecture, PowerPoint 
presentation, and 
videos 
~ 20 minutes of 
original presentation 
 
~ 10 minutes of 
condensed 
presentation 
The HPV vaccine is 
associated with which 
of the following 
adverse events? 
(select all that apply) 
a) Venous 
thromboembolism 
(VTE) 
b) Neurologic events 
c) Autoimmune 
events 
d) Localized 
injection site pain 
e) None of the 
above 
The nine-valent HPV 
vaccine has 
demonstrated ____ 
efficacy if given prior 
to the initiation of 
sexual activity. 
a) 92% 
b) 87% 
c) 96% 
d) 78% 
Which of the 
following has been 
found to be the most 
significant factor in 
determining HPV 
vaccine acceptance 
and initiation among 
parents and 
adolescents? 
a) Provider 
recommendation 
b) Amount of 
education 
provided 
c) Increased time for 
appointment 
d) Advertisement 
recommendation 
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Table 1. Practice Improvement Project Objectives and Assessment Questions (continued) 
Question Response Options Method of 
Instruction 
Length of 
Instruction 
Objective 3: Improve healthcare professionals’ level of comfort in the communication 
strategies used to improve HPV vaccination coverage rates 
Following the 
educational 
presentation, I have 
an increased 
understanding of 
HPV, the HPV 
vaccine, and 
communication 
strategies used to 
reduce missed 
opportunities and 
improve vaccine 
coverage. 
1) Strongly disagree 
2) Disagree 
3) Neutral 
4) Agree 
5) Strongly agree 
Lecture, PowerPoint 
presentation, and 
videos 
~ 40 minutes of the 
original presentation 
 
~ 20 minutes of the 
condensed 
presentation 
Following the 
educational 
presentation, I am 
more comfortable 
discussing HPV and 
the HPV vaccine with 
parents and 
adolescents. 
1) Strongly disagree 
2) Disagree 
3) Neutral 
4) Agree 
5) Strongly agree 
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CHAPTER 5. RESULTS1 
Presentation of Results 
Data were collected through the use of post-test questionnaires completed by healthcare 
providers, and HPV vaccination data was obtained from Sanford Health. The post-test 
questionnaires were collected immediately after completing the presentation. The Jamestown 
questionnaires were collected on the following dates: November 5, 2018, November 8, 2018, and 
November 20, 2018. The Valley City questionnaires were collected November 27, 2018. The 
Sanford Health data were collected in January 2019 from both Jamestown and Valley City 
clinics, as well as from the immunization strategy leader for Sanford Health in Sioux Falls, SD. 
Demographics 
 The demographic data was collected on the post-test questionnaires. The total number of 
participants between the two sites was 36. Three of the 36 participants were unable to stay for the 
complete presentation and were not able to complete the post-test questionnaire. Nearly half 
(n=15) of the participants were primary care providers, including physicians, nurse practitioners, 
and physician assistants. The remainder of the participants (n=18) were nursing staff, including 
registered nurses (n=10) and licensed practicing nurses (n=6), as well as other support staff 
working at the clinics. The level of experience for the participants ranged from less than one year 
to over 20 years. Please see Figure 3 for additional information.  
                                               
 
1 The material in this chapter was co-authored by Carly Hanson and Dr. Allison Peltier. Carly 
Hanson had primary responsibility for collecting samples in the field and for interviewing users 
of the test system. Carly Hanson was the primary developer of the conclusions that are advanced 
here. Carly Hanson also drafted and revised all versions of this chapter. Dr. Allison Peltier 
served as proofreader and checked the math in the statistical analysis conducted by Carly 
Hanson. 
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Figure 3. Healthcare professionals’ level of experience. 
Objective 1 
 The first objective of the project was to improve the level of knowledge of the HPV 
vaccine, safety, and efficacy for healthcare professionals. As previously discussed, there were 
four questions on the post-test questionnaire pertaining to objective one. The first question 
evaluated healthcare professionals’ level of knowledge of the current HPV vaccine dose-regimen 
for adolescents ages nine through fourteen years. The correct answer was option b. 2-dose 
regimen: now and six months (Meites, Kempe, & Markowitz, 2016). Of the 33 healthcare 
professionals who completed the post-test questionnaire, 93.9% (n = 31) chose the correct 
answer for the current dose-regimen recommendation for the age range. 
 The second question evaluated healthcare professionals’ knowledge of associated adverse 
events with receiving the HPV vaccine. Multiple answers were allowed for the question, as it 
was a select all that apply. Although the question was a select all that apply, there was only one 
correct answer. The correct answer was option d. localized injection site pain. VTE, neurologic 
events, and autoimmune events were additional options; however, they were not supported by 
research and not positively associated with the HPV vaccine (Arnheim-Dahlström et al., 2013; 
Bonanni et al., 2017; Lui et al., 2016). The correct answer was chosen 76.9% of the time. Of the 
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33 participants, 90.9% (n = 30) chose the correct answer but not necessary the correct 
combination since it was a select all that apply question. 
 The third question was used to evaluate healthcare professionals’ knowledge of vaccine 
efficacy. The correct answer was option c. 96% (Luckett & Feldman, 2016).  The results for the 
answer were split; however, only 42.4% (n = 14) of the healthcare professionals chose the 
correct answer. The other similar, yet incorrect answer (92%) was chosen by 54.5% (n = 18) of 
the healthcare professionals. 
The final question used to evaluate objective one assessed healthcare professionals’ 
knowledge of the most significant factor for HPV vaccination among adolescents. The correct 
answer was option a. provider recommendation (CDC, 2018g). Provider recommendation is the 
number one reason for HPV vaccination in the United States. It is considered to be key in 
parental acceptance and HPV vaccination uptake among the adolescent population (Perkins et 
al., 2014). Of the 33 healthcare professionals, 97% (n = 32) selected the correct answer. See 
figure 4 for additional information. 
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Figure 4. Responses to post-test questions 1-4. Evaluation of objective 1. * represents the correct 
answer. 
Objective 2 
 The second objective of the project was to reduce the number of missed opportunities for 
HPV vaccination among adolescents at each of the clinic sites. HPV vaccination and missed 
opportunity rates were monitored for 2 months prior to the practice improvement project and 
compared to HPV vaccination and missed opportunity rates at each of the clinic sites post-
intervention. The original age range was adolescents ages 11-17 years; however, due to data 
received from Sanford Health, the age range was expanded to include up to 26 years. Additional 
data regarding diagnoses at the missed opportunity visits and total number of HPV vaccines 
administered were collected for further evaluation. The total number of patient visits for ages 11-
14 years and 15-26 years for September 2018 through January 2019 were calculated for both 
Jamestown and Valley City clinics. 
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Missed opportunities. The overall total for each interval included ages 11-14 years and 
15-26 years. The overall total number of missed opportunities for HPV vaccination at the 
Sanford Jamestown Clinic was 322 in the two months prior to the educational intervention 
(September 20 – November 19, 2018), which is 30.3% of the total patient visits during the same 
time. Approximately 38.8% of patient visits ages 11-14 years and 28.9% of patient visits ages 
15-26 years were missed opportunities for HPV vaccination prior to educational intervention. 
The overall total number of missed opportunities was 294 for the two months following the 
intervention (November 20, 2018 – January 19, 2019), which is 31.5% of the total patient visits. 
Approximately 45.1% of patient visits ages 11-14 years and 29.2% of patient visits ages 15-26 
years were missed opportunities in the 2 months after the intervention. For a detailed breakdown 
of the missed opportunities for each age group and month below, please see Figure 5 and Table 
2. 
 
Figure 5. Percentage of missed opportunities for HPV vaccination at the Sanford Jamestown 
Clinic.  
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Table 2 
Sanford Jamestown Missed Opportunities for HPV Vaccination 
 
Sept 20-
Oct 19 
Oct 20-
Nov 19 
Nov 20-
Dec 19 
Dec 20-
Jan 19 
11-14 years 71 76 82 51 
15-26 years 459 457 446 355 
 
The Valley City clinic reported zero missed opportunities before and after the practice 
improvement project, which included all vaccinations for ages 11-26 years. The Valley City 
clinic checked their rates using two different methods to verify the results, EPIC data and NDIIS 
data. During the two months prior to the educational intervention in Valley City (September 27 – 
November 26, 2018), the clinic saw 314 patients ages 11-26 years. In the two months after the 
intervention (November 27, 2018 – January 26, 2019), 330 patients ages 11-26 years were seen. 
Non-HPV missed opportunities. At the Sanford Clinic in Jamestown, there were missed 
opportunities for TDaP and meningococcal vaccination as well. From September 20, 2018 
through November 19, 2018, there were 82 missed opportunities for TDaP and meningococcal 
vaccination for ages 11-26 years. The percentage of missed opportunities for TDaP and 
meningococcal vaccination was 7.7% for the two months prior to intervention. The number of 
missed opportunities for TDaP and meningococcal vaccination from November 20, 2018 through 
January 19, 2019 was 86 for ages 11-26 years. The percentage of missed opportunities for TDaP 
and meningococcal vaccination was 9.2% for the two months post-intervention. See Figure 6 for 
more information regarding a comparison of HPV missed opportunities to TDaP and 
meningococcal missed opportunities. As previously stated, Valley City Sanford did not have any 
missed opportunities for adolescent vaccinations, including TDaP, meningococcal, and HPV. 
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Figure 6. Percentage of missed opportunities before and after at Sanford Jamestown. 
Frequent diagnoses associated with missed opportunities. Frequent diagnoses used 
during missed HPV opportunities include the following: encounter for routine exam, sore throat, 
upper respiratory infection, sinusitis, attention deficit disorder (ADD), and immunizations due. 
At the Jamestown clinic, there were 16 visits with the diagnosis of ‘immunization due’ before the 
educational intervention, and there were 17 visits with this diagnosis after. There were 32 visits 
with diagnoses for routine exam or well child exam before the intervention, and this was reduced 
to 17 visits with these diagnoses after the intervention. Missed opportunities during visits for 
upper respiratory infection (URI), sinusitis, and sore throat were commonly noted during the 
evaluation time. Twenty-six visits for URI, sinusitis, or sore throat occurred pre-intervention, 
while 31 visits for URI, sinusitis, or sore throat occurred post-intervention. 
HPV vaccines given. The total number of HPV vaccines given for two months prior to 
the intervention (September 20, 2018 to November 20, 2018) was 47 at the Jamestown Sanford 
Clinic, which includes both clinic and state vaccine. The 47 doses of HPV vaccination account 
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for only 4.4% of the patient visits ages 11-26 years. This number is comparable to the total 
number of HPV vaccines given at the Jamestown Sanford Clinic for two months after the 
intervention (November 21, 2018 to January 20, 2019), which was 46. The 46 doses account for 
4.9% of the patient population seen. Twelve HPV vaccines were administered at the Valley City 
Sanford Clinic two months prior to the intervention (September 27, 2018 to November 26, 
2018), which was given at 3.8% of visits. Sixteen HPV vaccines were administered in the two 
months after the intervention (November 27, 2018 to January 27, 2019) at the Valley City 
Sanford Clinic, which accounts for 4.8% of the visits. 
HPV status for attributed patients. Sanford Health provided additional data regarding 
the HPV status for patients during each month. The data is separated into two groups based on 
age of the patient for each of the clinics. The age ranges are 11-14 years and 15-26 years. The 
number of patients with zero HPV doses, one dose, and completed were collected. The patients 
were also assigned to an active primary care provider and clinic through a process called 
attribution (Ambulatory Attribution Workgroup, 2019). The assignment to an active primary care 
provider is based on eligible encounters. Eligible encounters include an office visit, well child, 
OB office visit, nursing home visit, and pediatric visit. The encounter must be a face-to-face 
encounter and a completed appointment. The patients are assigned to the active provider seen 
most frequently in the past 27 months. Once the patient is assigned to a provider, they are then 
assigned to the provider’s clinic. Patient attribution is updated monthly and can change based on 
the patient’s attributed primary care provider. 
The percentage of patients with one dose and who completed the HPV vaccine series did 
not change significantly from before the practice improvement to after the project. The number 
of patients attributed to each clinic did vary slightly due to the attribution process. See figures 7 
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and 8 for additional information. It is important to note, not all attributed patients are seen each 
month at the clinic. Less than 15% of the attributed population ages 11-14 years is seen each 
month and less than 35% of the attributed population ages 15-26 years is seen each month at the 
Sanford Jamestown Clinic. Roughly 14% or less of the attributed population ages 11-14 years is 
seen each month at the Sanford Valley City Clinic and less than 25% of the attributed population 
ages 15-26 years is seen monthly. See figure 9 for additional information about the percentage of 
attributed patients who were seen each month. 
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Figure 7. Sanford Jamestown HPV vaccination monthly coverage percentages. 
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Figure 8. Sanford Valley City HPV vaccination monthly coverage percentages. 
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Figure 9. Percentage of attributed patients seen at Sanford Jamestown and Sanford Valley City.
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Objective 3 
 The third objective was to improve the healthcare professionals’ level of comfort in the 
new communication strategies discussed during the educational presentation. Two questions on 
the post-test questionnaire were used for the evaluation and scored on a 5-point Likert scale from 
strongly disagree to strongly agree. The first question evaluated healthcare professionals’ beliefs 
about their level of understanding of HPV, the vaccine, and communication strategies and if they 
felt their understanding and comfort of these topics increased after attending the educational 
intervention. The average score was 3.97. Of the 33 healthcare professionals who completed the 
questionnaire, 75.8% (n = 25) either agreed or strongly agreed with the statement. There were 
18.2% (n = 6) of those who attended who strongly disagreed with the statement. Please see figure 
8 for additional information. 
 
Figure 10. Percentages of increased understanding from healthcare professionals post-
intervention. 
 The second statement used to evaluate objective three appraised healthcare professionals’ 
level of comfort in using the new communication techniques for discussing HPV with parents 
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and adolescents after attending the educational session. The average score was 4.06. Of those in 
attendance, 78.8% (n = 26) positively responded to the statement by either agreeing or strongly 
agreeing. The number who disagreed was the same for the second question at 18.2% (n = 6). 
Please see figure 9 for additional information. 
 
Figure 11. Percentage of increased comfort for healthcare professionals post-intervention. 
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CHAPTER 6. DISCUSSION & RECOMMENDATIONS 
Interpretation of Results 
Post-test Results 
 Overall, a majority (n=25) of the healthcare professional participants reported an increase 
in level of understanding of HPV, the HPV vaccine, and communication strategies to reduce 
missed opportunities for vaccination and improve coverage. The correct answer was selected on 
the post-test a majority of the time for questions one through four, which were used to evaluate 
objective one. The post-test results indicate an increase in participants’ knowledge; however, 
there is no baseline pre-test for comparison. It is critical to prioritize effects to facilitate 
healthcare professionals understanding and recommendations for HPV vaccination (Pierre-Victor 
et al., 2017b). Interventions, such as educational sessions, that increase healthcare professionals’ 
understanding can increase HPV vaccination coverage according to Fu et al. (2014). 
The results for question three about the efficacy of the HPV vaccine in the HPV-naïve 
population did vary with an incorrect answer being chosen a majority of the time; however, the 
most common answer chosen was only four percent different than the correct answer of 96%. 
Both answers were greater than 90%. Gaps in healthcare professionals’ knowledge and lack of 
strong recommendation are known factors for the lag in HPV vaccination uptake in comparison 
to the required adolescent vaccines (Farmar et al., 2016; Tom et al., 2016). Research has shown 
how essential it is to increase provider knowledge and strengthen the recommendation for HPV 
vaccination in order to improve vaccination uptake and completion rates (Rand et al., 2018). 
The average rating for increased level of understanding after attending the practice 
improvement intervention was 3.97 on a 5-point Likert scale, demonstrating a positive response 
from the healthcare professionals in attendance. The average rating for increased level of comfort 
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with new communication strategies to reduce missed opportunities for HPV vaccination was 
4.06 on a 5-point Likert scale, which also demonstrated positive results from many of the health 
professionals. The positive results support the available evidence about the importance of 
provider knowledge and subsequent recommendation for HPV vaccination in the adolescent 
population (Brown et al., 2015). The results also indicate project objective three was met. 
Provider recommendation is critical and remains to be a key area for HPV vaccination uptake 
research (Hansen et al., 2016). 
Missed Opportunity Results 
When further evaluating objective two and the rate of missed opportunities for HPV 
vaccination, it is noted there was no change from before project implementation to after. The rate 
of missed opportunities at both Jamestown Sanford and Valley City Sanford did not change. 
However, the rate of missed opportunities at routine physical exams and immunization due visits 
did decrease at the Jamestown clinic after the educational intervention. Routine exam missed 
opportunities was 32 in the two months prior to intervention and decreased to 17 in the two 
months after the intervention. The immunization due visit rate of missed opportunities did not 
decrease following implementation of the educational sessions. 
The overall lack of change in rate of missed opportunities is supported by evidence 
stating educational interventions alone are not enough to significantly decrease the rates of 
missed opportunities (McLean et al., 2017). A multifaceted approach including provider and 
staff education has been shown to significantly impact the rate of missed opportunities (Rand et 
al., 2018). Additional evidence suggests implementation of recall systems to increase HPV 
vaccination uptake may help to reduce the number of missed opportunities (McLean et al., 
2017). 
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State & County Rate Comparison 
 Comparison of Sanford Jamestown and Valley City rates to state and county rates is 
important to gain an understanding of the effectiveness of the educational intervention; however, 
it is difficult due to the difference in the age groups. State and county level statistics are for ages 
11-17 years, while Sanford statistics are for ages 11-14 years and 15-26 years. For the 
comparison, up-to-date rates for county and state are compared with completed rates at each of 
the intervention clinics. In January 2019, Sanford Jamestown HPV vaccination coverage for ages 
11-14 years was 22% for 1-dose and 44.8% for completed HPV vaccination series. The coverage 
for ages 15-26 years was 7.4% with 1-dose and 58.6% completed. The Stutsman County 
completed rate was 73.07% for adolescents ages 11-17 years in 2018 (NDIIS, 2018). Therefore, 
Sanford Jamestown remained below the county rates after educational implementation. 
 Sanford Valley City HPV coverage for ages 11-14 years was 23.2% with 1-dose and 30% 
completed in January 2019. The coverage for ages 15-26 years was 3.9% with 1-dose and 52.8% 
completed. Barnes County coverage for ages 11-17 years is 65% for 1-dose and 55.64% for up-
to-date (NDIIS, 2018). In comparison to Barnes County, Sanford Valley City remains 
significantly below the county coverage rates for 1-dose. The coverage for ages 15-26 being 
completed is closer to county levels but remains behind after the educational intervention, as 
discussed in the following paragraph.  
 The coverage rate for completed HPV vaccination in Jamestown for ages 15-26 is above 
state levels at 57.3% completed, whereas the North Dakota coverage rates for ages 11-17 years is 
67.6%. Sanford Valley City is slightly behind the completed rates for ages 15-26 at 52.6%. The 
rates for 1-dose completion at each of the intervention clinics were significantly behind the state 
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rates for all ages. The state rate for 1-dose is 67.6% for ages 11-17 years. Sanford Jamestown had 
a 1-dose rate of 7.5%, and Sanford Valley City has a 1-dose rate of 3.7%.  
Limitations 
 The practice improvement project was associated with several limitations. The first 
limitation was a small sample size. Overall, 33 participants were able to complete the entire 
educational session and post-test questionnaire. A small sample size negatively impacts the 
accuracy of the results and does not allow the results to be generalized (McClave & Sincich, 
2017). The total participants were split between the two healthcare locations as well. 
 A second limitation was the limited number of implementations of the practice 
improvement project educational sessions. The project was implemented four times: three in 
Jamestown and one in Valley City. There is a larger number of employees at the Jamestown 
Sanford location, which is why the project was implemented in this location additional times. 
The third time in Jamestown was a condensed version of the presentation due to implementing 
during the weekly provider meeting. Increased amounts of implementation sessions may have 
increased the sample size. 
 An additional limitation was the type of data collected. The HPV statistics were collected 
in aggregate form. Aggregate form was used to protect patient and provider identities; however, 
it does not allow for the results to be tailored to the individual providers. The aggregate data also 
does not allow details to be known about the missed opportunity visits. Additional helpful details 
about the reasoning for a missed opportunity, such as an acute illness, parental/patient refusal, or 
inaccurate immunization records, would be helpful in learning more about the various causes of 
missed opportunities at each facility. Knowledge regarding the healthcare providers associated 
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with each missed opportunity visit would also help to know if certain providers at the facilities 
have higher rates of HPV missed opportunities and may benefit from further education. 
 A forth limitation is the varying age ranges for the aggregate data regarding HPV 
coverage rates for each clinic. The data were only available in set ages from 11-14 years and 15-
26 years. The target ages for the practice improvement project were ages 11-17 years; however, 
the ages of 18-26 years were included in the results and comparison. Including the additional 
ages possibly skewed the data for coverage rates and the comparison to state and county level 
statistics. 
 A fifth limitation is the amount of time spent monitoring the data. The data were 
monitored for 2 months prior to and after the educational intervention at each facility. The 
amount of time spent monitoring the HPV statistics may not have been adequate to fully see the 
changes after implementation. Fewer patients ages 11-14 years and 15-26 years were seen in the 
clinic after the educational intervention than before the intervention. Rand et al. (2018) recorded 
data for a 12-month period. Additionally, the limited timeframe for implementation did not allow 
for the presentation to be recorded and made available to additional healthcare professionals, 
which may have increased the number of participants and access to the intervention. A recording 
of the PowerPoint presentation with a voiceover could have enhanced sustainability as well. 
 Another limitation may be the reliability of the data. The Valley City Sanford Clinic 
reported zero missed opportunities for vaccination; however, the rates of HPV vaccination 
coverage in January 2019 were only 30% for ages 11-14 years and 52% for ages 15-26 years. 
The percentage of adolescents who had not received any HPV vaccination was high. 
 The final limitation is found within the missed opportunity data and patient visit numbers. 
Not all patients ages 15-26 years were eligible to receive the HPV vaccine due to pregnancy or 
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other contraindications. The patients were still noted on the missed opportunity data, as well as 
the total visit numbers for each month because according to health maintenance data from 
Sanford, the patients were due for the vaccine. Further exclusion parameters could have resolved 
this issue and lead to more accurate data and statistics. 
Recommendations 
 Due to the positive response from healthcare professional participants, it is reasonable to 
recommend continued research into the impact of educational seminars on the rates of missed 
opportunities for HPV vaccination. Brief educational seminars and updates could be instituted 
quarterly or an annual seminar is another option. Despite the lack of a significant decrease in the 
rate of missed opportunities for vaccination and overall HPV vaccination rates, continued 
healthcare professional education is warranted. Educational intervention regarding the 
significance of accurate and consistent provider recommendation for HPV vaccination can 
increase coverage rates (Krantz et al., 2017). 
One recommendation is to expand the research and implementation opportunity to 
include an online module. Since the practice improvement project was implemented at Sanford 
Health facilities, the expanded research could include implementing a Sanford Success Center 
online module or Sanford Learn. The online module would contain the same information and 
details, yet be more easily accessible. Expanding the research to include online modalities 
increases the sample size and demographics. The online module also allows for participants to 
access it at a time that works best for them and could be available for a certain length of time. 
The expanded research would focus on family practice healthcare professionals. The Sanford 
Learn module could be assigned to certain staff on an annual basis and updated as needed. 
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 An additional option for Sanford Health is to implement quarterly staff questions 
pertaining to HPV vaccination. Nursing staff are required to participate in staff questions on a 
monthly basis to verify knowledge of specific topics. HPV vaccination could be implemented as 
one of the key topics. Additional healthcare professionals, including providers, could also 
participate in the questions. Rand et al. (2018) reported including all staff in multifaceted 
interventions to increase HPV vaccination to be significant in improved facility rates. Quarterly 
questions would be a method of continued reinforcement of the information previously learned 
through educational sessions. Consistent questions and staff education, along with system level 
changes, are more sustainable and can increase HPV vaccination rates (McLean et al., 2017). 
 The long-term recommendation for the project is to continue implementation through an 
online module and expand the participant pool. The expanded pool would include the health 
professionals within the pediatric specialty. The overall goal is for HPV vaccination rates to 
increase to the Healthy People 2020 goal of over 80% and reduce the rate of missed 
opportunities (ODPHP, 2018). 
Implications for Practice 
 The practice improvement project impacted 33 healthcare professionals, including 
physicians, advanced practice providers, and nursing staff. The research and data collected adds 
to the available literature regarding the impact of healthcare professional-focused educational 
interventions. The significance of providing education to all staff can create a group culture that 
encourages HPV vaccination (Wolynn, 2018). Rand et al. (2018) support HPV vaccination 
interventions that involve all staff as well, noting it can have a larger impact on the results. 
 New information was provided during the practice improvement project to increase 
healthcare professional knowledge about the significance of rising HPV-associated cancers, such 
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as oropharyngeal cancer. The rates of oropharyngeal HPV-positive cancer are increasing and 
predicted to surpass the rates of HPV-associated cervical cancer by 2020 (Selcuk, 2016). The 
significance of protecting against rising cancers is known, but additional healthcare professional 
education is important to continue to recommend vaccination. 
 With the implementation and recommendation of a 2-dose series by the ACIP and CDC, 
it is critical to provide education to all staff (Meites, Kempe, & Markowitz, 2016). HPV-9 
vaccination rates continue to lag behind the other adolescent vaccinations required. The 2-dose 
series has the potential to improve vaccination rates and increase coverage. In addition to the 2-
dose schedule for ages 11-14 years, the ACIP is also investigating an extended schedule for ages 
27-45 years (Markowitz, 2018). The extended ages were approved by the FDA in 2018 in hopes 
to increase protection against HPV-associated complications (FDA, 2018b). With the new 
extended ages, coverage rates will continue to be below the Healthy People 2020 goal of 80% 
unless interventions are used to increase provider recommendations and coverage rates (ODPHP, 
2018). 
 The impact of a successful HPV vaccination program is noted by the current rates of 
HPV-associated complications in Australia (Hall et al., 2018). Australia was one of the first 
countries to start a national HPV vaccination program in 2007 for girls that expanded in 2013 for 
boys (Patel et al., 2018). The program originally administered the quadrivalent HPV vaccine and 
only recently changed from the 2-dose series to the nine-valent HPV vaccine in January 2018. A 
substantial decline in the rates of genital warts and cervical disease were reported and directly 
linked with the national vaccination program. Australia reports HPV-associated diseases could 
be potentially eliminated if the vaccination program continues, along with screening for disease. 
  76 
 Currently in Australia, the HPV vaccine coverage for girls is greater than 78% and 
greater than 72% for boys (Patel et al., 2018). The coverage rates are below the Healthy People 
2020 goal of 80% but are significantly higher than current coverage rates in the United States 
(CDC, 2018a; ODPHP, 2018). According to Patel et al. (2018), mortality rates for cervical 
cancer are predicted to continue to decrease and reach one new case per 100,000 annually by the 
year 2034. Due to the HPV vaccination program and cervical cancer screening in Australia, the 
rate of new cervical cancer diagnoses is estimated to decrease to less than six per 100,000 
annually by 2020. If boys were not included in the vaccination program, a delay of at least 2 
years in cervical cancer elimination is anticipated. The findings from Australia demonstrate the 
need for improved vaccination rates in the U.S. to reduce the rates of HPV-related complications, 
which is why this practice improvement project and future projects are needed. 
Implications for Future Research 
 The findings from the practice improvement project revealed a continued need for 
intervention to reduce missed opportunities for HPV vaccination and increase vaccination 
coverage, especially in rural areas. The project intervention did increase healthcare professional 
understanding of HPV and confidence in communication strategies. Despite the increased 
knowledge, the rate of missed opportunities and HPV vaccination coverage did not improve 
significantly after project implementation. Of importance to note is the rate of missed 
opportunities at routine exams, including well child and physicals, did decrease from 32 before 
implementation to 17 after implementation at the Sanford Jamestown Clinic. The rates of missed 
opportunities at problem focused and immunization due visits remained unchanged. Further 
research is needed to understand the best methods to increase HPV vaccination coverage in rural 
areas and reduce the number of missed opportunities. 
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 One area of focus for future research is the idea of implementing a multifaceted 
approach. The new approach could use alternative options for educational sessions, including 
online modules. The multifaceted approach would also incorporate provider feedback, as other 
studies have shown feedback as a key element for improving vaccination coverage (Moore et al., 
2017; Rand et al., 2018). It is beneficial to include all staff in the approach to increasing HPV 
vaccination coverage, including the option of a standard process that allows for nursing support 
staff to begin the vaccine discussion (Farmar, 2016; Rand, 2018). 
 Research is needed to focus on the creation of a catch-up program and recall system for 
the expanded ages of the HPV vaccine. Pending ACIP approval, the nine-valent HPV vaccine 
will be needed for the additional ages of 27-45 years (Markowitz, 2018). Research evaluating the 
best methods for catch-up notification and recall after series initiation is needed. Limited data is 
available regarding methods with positive outcomes. 
 Another area of focus for future research is the rural population. Limited research is 
available regarding the rural population in the Midwest. A large portion of available research 
regarding HPV vaccination coverage is in rural Appalachia (Oldach & Katz, 2012). Further 
investigation into the barriers for vaccination uptake and interventions to reduce missed 
opportunities in the rural Midwest is needed. The future research could evaluate the differences 
in coverage among the American Indian population in the area as well. 
 A final topic for consideration is the expansion of HPV intervention research to include 
new partners. Future research could consider partnering with student health at local universities, 
such as North Dakota State University. New partners allow for increased populations with 
varying demographics to be reached. With the expanded population and ages, research could 
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evaluate the barriers to vaccination coverage, as well as types of interventions that would work 
best for the population. 
Application to Other DNP Roles 
 The rates of missed opportunities for HPV vaccination and coverage lag behind other 
adolescent vaccines is well documented. Nurse practitioners working in primary care and family 
practice are on the front lines. Primary care is a key setting for vaccination and education 
regarding HPV. Increased understanding of barriers to vaccination and to working with the rural 
adolescent population can help nurse practitioners to provide a higher-level quality of care. The 
communication strategies provided can be used to discuss additional adolescent topics, such as 
sexual health or health hygiene. The significance of a recommendation from a healthcare 
professional is well-known, no matter the topic of conversation. 
 Healthy People 2020 (ODPHP, 2018) goals include increased immunization rates, which 
coordinates with the goal of nurse practitioners to ensure appropriate primary prevention is being 
provided. Immunizations are a foundation piece of primary prevention. Nurse practitioners strive 
to improve the health of the population and provide education to patients. Increased 
immunization and use of primary prevention has the potential to improve health and reduce the 
rates of HPV-related complications. 
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Objectives
• Identify HPV & associated complications
• Understand the HPV vaccine, safety, 
efficacy, & statistics
• Identify the barriers of vaccination 
coverage
• Understand what can be done to improve 
coverage rates
• Increase confidence levels in new 
communication strategies
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What is HPV?
• Virus with over 150 different strains
• Sexually transmitted infection (STI)
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Why is HPV a problem?
• Cancer
– Cervical
– Oropharyngeal
– Vaginal/vulvar
– Penile
– Anal
• Genital warts
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What can we do to reduce the 
burden of HPV?
VACCINATE
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HPV Vaccine Schedule
• Males & Females 9-14 years
– 2-dose regimen: now & 6 months
• Males 15-21 years & Females 15-26 years
– 3-dose regimen: now, 1-2 months, & 6 months
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Vaccine Safety
• Monitored by FDA
• Pain at injection site is the most common 
adverse event
• No significant risk increase for developing 
VTE, autoimmune, or neurologic adverse 
event
STUDENT FOCUSED • LAND GRANT • RESEARCH UNIVERSITY
Vaccine Efficacy
• 96% efficacy demonstrated against HPV 
6, 11, 16, 18, 31, 33, 45, 52, & 58
• Future II trial
• Estimated protection against cervical 
cancer will increase to 90%
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Adolescent HPV Immunization Rates: 
Years 13-17
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HPV Vaccination Coverage: 
Adolescents 13-17 years
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Barriers
Lack of 
Parental 
Knowledge
Lack of 
Provider 
Support
Missed 
Opportunities
Lack of 
Follow-Up
HPV 
Vaccination 
Myths & 
Parental 
Concerns
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HPV Myths & Parental 
Concerns
• Increased risk of sexual activity
• Cost
• Safety
• Not necessary due to abstinence
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Lack of Parental Knowledge
• Not receiving education or 
recommendations from healthcare 
professionals
– Correlates with the amount of time providers 
spend educating
• Deficits among parents of male and 
female adolescents
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Lack of Provider Support
• Provider ambivalence
• Lack of time
• Lack of provider knowledge
• Lack of strong recommendation
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Missed Opportunities
• Definition: HPV vaccine not provided but 
other adolescent vaccines are provided
• Over 90% of problem-focused visits
• Every visit is an opportunity to educate 
and vaccinate
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Lack of Follow-Up
• Linked with HPV completion rates
• Need to remind and educate about the 
importance of series completion
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How do we improve HPV 
immunization acceptance?
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Communication Strategies
Framing
Bundling
Provider 
Recommendation
Presumptive 
Communication
Normalizing
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Framing
• How HPV vaccination is discussed and 
compared to other adolescent vaccines
• Optional approach
• Loss-framing messages
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Bundling
• Communication technique
• Sandwich the HPV vaccine
– TDaP, HPV, Meningococcal
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Provider Recommendation
• #1 reason for vaccine initiation and 
completion
• Provide education & knowledge + a clear 
and strong recommendation
• Be consistent and remember the framing
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Presumptive Communication
• Frame and recommend HPV vaccination 
with the result of vaccination today in the 
statement
• Continue to pursue HPV vaccination at 
every visit
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Normalizing
• Do not single out the HPV vaccine
• Used with Bundling
• Makes the HPV vaccine appear to be of 
equal importance with the other 
adolescent vaccines
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https://www.youtube.com/watch?feature=oembed&v=zyrrRQgtlr
s
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https://www.youtube.com/watch?feature=oembed&v=MS3gCZra
dTw
STUDENT FOCUSED • LAND GRANT • RESEARCH UNIVERSITY
https://www.youtube.com/watch?feature=oembed&v=oFr8
0_RAhIQ
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Appointment Scheduling
• 65% of parents expect the clinic to 
schedule
• 52% of providers explain the HPV 
schedule but expect the parents to 
schedule
• Scheduled follow-up = higher completion 
rates
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Education
• Focus on cancer prevention
• Prioritize!
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Summary
• HPV complications continue to exist
• HPV immunization rates lag behind other 
adolescent immunizations
• Nine-valent HPV vaccine demonstrated to 
be safe & effective
• Healthcare professionals are on the 
frontlines for improving vaccination rates 
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HPV Immunization: Reducing 
Missed Opportunities through 
Enhanced Provider Knowledge 
and Communication Strategies
Carly Hanson, DNP-S
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Objectives
• Identify HPV & associated complications
• Understand the HPV vaccine, safety, 
efficacy, & statistics
• Identify the barriers of vaccination 
coverage
• Understand what can be done to improve 
coverage rates
• Increase confidence levels in new 
communication strategies
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What is HPV &
why is HPV a problem?
• Sexually 
transmitted 
infection
• 150+ serotypes
• Cancer
– Cervical
– Oropharyngeal
– Vaginal/vulvar
– Penile
– Anal
• Genital warts
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What can we do to reduce the 
burden of HPV?
VACCINATE
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HPV Vaccine Schedule
• Males & Females 9-14 years
– 2-dose regimen: now & 6 months
• Males 15-21 years & Females 15-26 years
– 3-dose regimen: now, 1-2 months, & 6 months
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Vaccine Safety
• Monitored by FDA
• Pain at injection site is the most common 
adverse event
• No significant risk increase for developing 
VTE, autoimmune, or neurologic adverse 
event
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Vaccine Efficacy
• 96% efficacy demonstrated against HPV 
6, 11, 16, 18, 31, 33, 45, 52, & 58
• Future II trial
• Estimated protection against cervical 
cancer will increase to 90%
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Adolescent HPV Immunization Rates: 
Years 13-17
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HPV Vaccination Coverage: 
Adolescents 13-17 years
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Barriers
Lack of 
Parental 
Knowledge
Lack of 
Provider 
Support
Missed 
Opportunities
Lack of 
Follow-Up
HPV 
Vaccination 
Myths & 
Parental 
Concerns
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HPV Myths & Parental 
Concerns
• Increased risk of sexual activity
• Cost
• Safety
• Not necessary due to abstinence
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Lack of Parental Knowledge
• Not receiving education or 
recommendations from healthcare 
professionals
– Correlates with the amount of time providers 
spend educating
• Deficits among parents of male and 
female adolescents
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Lack of Provider Support
• Provider ambivalence
• Lack of time
• Lack of provider knowledge
• Lack of strong recommendation
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Missed Opportunities
• Definition: HPV vaccine not provided but 
other adolescent vaccines are provided
• Over 90% of problem-focused visits
• Every visit is an opportunity to educate 
and vaccinate
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Lack of Follow-Up
• Linked with HPV completion rates
• Need to remind and educate about the 
importance of series completion
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How do we improve HPV 
immunization acceptance?
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Communication Strategies
Framing
Bundling
Provider 
Recommendation
Presumptive 
Communication
Normalizing
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Framing
• How HPV vaccination is discussed and 
compared to other adolescent vaccines
• Optional approach
• Loss-framing messages
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Bundling
• Communication technique
• Sandwich the HPV vaccine
– TDaP, HPV, Meningococcal
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Provider Recommendation
• #1 reason for vaccine initiation and 
completion
• Provide education & knowledge + a clear 
and strong recommendation
• Be consistent and remember the framing
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Presumptive Communication
• Frame and recommend HPV vaccination 
with the result of vaccination today in the 
statement
• Continue to pursue HPV vaccination at 
every visit
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Normalizing
• Do not single out the HPV vaccine
• Used with Bundling
• Makes the HPV vaccine appear to be of 
equal importance with the other 
adolescent vaccines
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Appointment Scheduling
• 65% of parents expect the clinic to 
schedule
• 52% of providers explain the HPV 
schedule but expect the parents to 
schedule
• Scheduled follow-up = higher completion 
rates
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Education
• Focus on cancer prevention
• Prioritize!
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Summary
• HPV complications continue to exist
• HPV immunization rates lag behind other 
adolescent immunizations
• Nine-valent HPV vaccine demonstrated to 
be safe & effective
• Healthcare professionals are on the 
frontlines for improving vaccination rates 
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APPENDIX D. TRANSCRIPTION OF HPV RECOMMENDATION VIDEOS 
Video Clip 1: Dr. Alix Casler describes how she recommends HPV vaccine 
When I recommend preteen vaccines, I recommend all three of the vaccines that we 
intend to do the same way basically. So here are three vaccines that we want to do. I do give a 
little information about each vaccine because that is my informed consent, just like when I talk 
about infant vaccines. I can talk about all three preteen vaccines in about a minute and have my 
informed consent done at the same time and kind of avoid the too much information thing. 
 So this is how I present things to parents, “Today, there are three vaccines that I’d like to 
do. The first one is the meningococcal vaccine which prevents a very, very rare but potentially 
very serious infection that could cause meningitis and when it does it’s uniformly devastating 
and potentially really deadly. The second one prevents the HPV infection which is extremely 
common. In fact, most of us get HPV in our lives and can go on to cause multiple different forms 
of cancers. That vaccine is given in a series of two. The second one would be given six to twelve 
months from now. And then the last one is the one that most people know about that’s the 
tetanus booster or the TDaP, which vaccinates against tetanus, diphtheria, and pertussis, which is 
whooping cough. If your child gets whopping cough, they could have a bad cough for two to 
three months, which is not fun. But really the big reason that we vaccinate big kids and 
grownups against pertussis, or whooping cough, is to protect babies who could die from that. Do 
you have any questions about those?” Usually parents don’t. about 80% of parents say, “Ok, that 
makes sense.” 
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Video Clip 2: Dr. Wolynn discusses how his office routinely recommends HPV vaccine 
 We really try and make sure that everybody is on board with the importance of the HPV 
vaccine, that includes people that are answering phones, that are in the billing department, 
certainly all of our clinical staff. We want them to understand with how common this virus is, 
how common the infections are. If everybody’s onboard, then we have an office culture that is 
shared and everybody recognizes that we’re often times the best chance for that child to become 
protected against cancers and diseases that they will potentially face if they are exposed and 
infected. 
Video Clip 3: Talking with parents who decline HPV vaccine 
 When a parent turns down the HPV vaccine, first of all I ask them what I can do or say to 
help them change their mind. that’s for sure. I ask them whether there are any specific conerns 
that they have that I can address. I ask them if they would mind reviewing some excellent 
information about the vaccine. And in my own mind, I really, really define the fact that they just 
haven’t said yes yet. It isn’t that they’ve said no, that they’re never going to do it. I don’t believe 
that most parents who say no are going to say no forever. I believe that most parents who say no, 
just aren’t adequately educated. 
 I do let them know that I would like to follow up with them. I actually really like, there’s 
one provider who I talk to who actually schedules a follow-up appointment to talk to them about 
it again in a month or two. I think that’s a great idea. And sometimes I do that. But the big thing 
in my mind, I know that the next time we talk we’re going to pick it up where we left. And I do 
tell parents, “You know I’m sorry that I keep bringing this up with you. But I really feel that it’s 
my responsibility to protect your child as best as I can. I feel like if I haven’t used my big mouth 
and said it to the point where you hear it and understand it and are ok with it, then if your child 
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later in life has a disease that I could have prevented by trying a little bit harder; I’m not going to 
be able to live with myself. I’m going to feel like I didn’t do a good enough job in helping you to 
say yes.” 
  110 
APPENDIX E. HEALTHCARE PROFESSIONAL INVITATION EMAIL 
 
Revised August 7, 2012 1 
 
 
NDSU  North Dakota State University 
   Department of Nursing 
   College of Health Professions 
   Dept 2670 
   PO Box 6050 
   Fargo, ND 58108-6050 
   701.231.5692 
 
HPV Immunization: Reducing Missed Opportunities through Enhanced Provider 
Knowledge and Communication Strategies 
 
 
Dear Participants 
 
My name is Carly Hanson.  I am a graduate student in the Doctor of Nursing Practice 
program at North Dakota State University, and I am conducting a practice improvement 
project to reduce the numbers of missed opportunities for HPV immunization and 
enhance knowledge of HPV and the HPV vaccine. The project will also enhance 
communication strategies regarding the HPV vaccine and how to address parental 
concerns.  It is our hope, that with this practice improvement project, we will improve 
healthcare professionals’ level of knowledge and comfort with HPV immunization, as 
well as improve knowledge of barriers for vaccination and the impact of missed 
opportunities for vaccination. 
 
Because you are healthcare professional, you are invited to take part in this practice 
improvement project.  Your participation is entirely your choice, and you may change 
your mind or quit participating at any time, with no penalty to you. 
 
It is not possible to identify all potential risks in practice improvement projects, but we 
have taken reasonable safeguards to minimize any known risks. There are minimal 
risks associated with completing the educational presentation. 
 
By taking part in this project, you may benefit by improving your knowledge of HPV, the 
HPV vaccine, and vaccine safety and efficacy. Additional benefits include improving 
your knowledge of missed opportunities and level of comfort with communication 
strategies used to improve HPV vaccination uptake and series completion. However, 
you may not get any benefit from being in this project. Benefits to others are likely to 
include enhanced patient and parent satisfaction of healthcare through the delivery of 
knowledge and provider recommendations using key communication techniques and 
education. Improved HPV vaccination coverage and series completion are additional 
potential benefits of this project. 
 
It should take about five minutes to complete the post-test questionnaire including 
demographics, healthcare professional knowledge of HPV and the HPV vaccine, and 
level of comfort with communication strategies. Lunch will not be provided; however, 
there will be snacks and refreshments. There will also be a drawing for a $10 gift card. 
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 Revised August 7, 2012 2 
 
This study is anonymous.  That means that no one, not even members of my 
dissertation team, will know that the information given comes from you. 
 
If you have any questions about this project, please contact me at 605-941-5049 or 
carly.hanson@ndsu.edu. You may also contact my advisor, Dr. Allison Peltier at 701-
224-3820 or Allison.Peltier@ndsu.edu. 
 
You have rights as a participant.  If you have questions about your rights or complaints 
about this research, you may talk to the researcher or contact the NDSU Human 
Research Protection Program at 701.231.8995, toll-free at 1-855-800-6717, by email at 
ndsu.irb@ndsu.edu, or by mail at:  NDSU HRPP Office, NDSU Dept. 4000, P.O. Box 
6050, Fargo, ND 58108-6050. 
 
By attending the educational presentation, you are giving your consent and are freely 
making the decision to participate in this practice improvement project. 
 
Thank you for your taking part in this project. If you wish to receive a copy of the results, 
please contact me or my advisor. 
 
 
Sincerely, 
 
 
Carly Hanson, DNP-S, BAN, RN 
Department of Nursing 
North Dakota State University, Fargo, ND 
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APPENDIX F. POST-TEST QUESTIONNAIRE 
 
HPV Immunization: Reducing Missed Opportunities through Enhanced Provider Knowledge and 
Communication Strategies 
Post-Test Questionnaire 
Demographics 
1. Please Indicate your current position 
  Physician 
  Nurse Practitioner 
  Physician Assistant 
  RN 
  LPN 
  CNA 
  Other __________ 
2. Please indicate your years of clinical experience 
  Less than 1 year 
  1 – 4.9 years 
  5 – 9.9 years 
  10 – 14.9 years 
  15 – 19.9 years 
  20 + years 
 
Please choose the correct answer. 
1. For both males and females ages 9 – 14 years, what is the correct HPV vaccine dose regimen? 
a. 2-dose regimen: now & 3 months 
b. 2-dose regimen: now & 6 months 
c. 3-dose regimen: now, 1-2 months, & 6 months 
d. 3-dose regimen: now, 1 month, & 3 months 
2. The HPV vaccine is associated with which of the following adverse events (select all that apply) 
a. Venous thromboembolism (VTE) 
b. Neurologic events 
c. Autoimmune events 
d. Localized injection site pain 
e. None of the above 
3. The nine-valent HPV vaccine has demonstrated _____ efficacy if given prior to the initiation of sexual 
activity? 
a. 92% 
b. 87% 
c. 96% 
d. 78% 
4. Which of the following has been found to be the most significant factor in determining HPV vaccine 
acceptance and initiation among parents and adolescents? 
a. Provider recommendation 
b. Amount of education provided 
c. Increased time for appointment 
d. Advertisement recommendation 
 
Indicate your opinion about the following statements using the scale below: 
1 = Strongly 
Disagree 
2 = Disagree 
 
3 = Neutral 
 
4 = Agree 5 = Strongly 
Agree 
1. Following the educational presentation, I have an increased understanding of HPV, the HPV vaccine, 
and communication strategies used to reduce missed opportunities and improve vaccine coverage. 
  1   2   3   4   5 
2. Following the educational presentation, I am more comfortable discussing HPV and the HPV vaccine 
with parents and adolescents. 
  1   2   3   4   5
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APPENDIX G. HANDOUTS PROVIDED AT EDUCATIONAL INTERVENTION 
  
Talking to Parents 
about HPV Vaccine 
Recommend HPV vaccination in the same way and on the same day as all adolescent vaccines. You can say, “Now that your 
son is 11, he is due for vaccinations today to help protect him from meningitis, HPV cancers, and whooping cough. Do you have 
any questions?” Remind parents of the follow-up shots their child will need and ask them to make appointments before they leave.
Why does my child need 
HPV vaccine?  
HPV vaccine is important because 
it prevents infections that can 
cause cancer. That’s why we need 
to start the shot series today. 
How do you know the 
vaccine works? Studies continue to prove HPV vaccination works extremely well, 
decreasing the number of infections
and HPV precancers in young 
people since it has been available.
 
Why do they need
HPV vaccine at such
a young age?
Like all vaccines, we want to give 
HPV vaccine earlier rather than 
later. Getting the vaccine now 
protects your child long before 
they are ever exposed. If you wait 
until your child is older, he/she 
may end up needing three shots 
instead of two.
Why do boys need the 
HPV vaccine?
HPV vaccination can help prevent 
future infections that can lead to 
cancers of the penis, anus, and 
back of the throat in men.
Are all of these vaccines 
actually required? I strongly recommend each of 
these vaccines and so do experts 
at the CDC and major medical 
organizations. School entry 
requirements are developed for 
public health and safety, but don’t 
always reflect the most current 
medical recommendations for 
your child’s health. 
Would you get HPV 
vaccine for your kids? Yes, I gave HPV vaccine to my child (or grandchild, etc.) when 
he was 11, because I wanted to 
help protect him from cancer in 
the future.
What diseases are 
caused by HPV?
Some HPV infections can cause 
cancer—like cancer of the cervix 
or in the back of the throat—but 
we can protect your child from 
these cancers in the future by 
getting the first HPV shot today.
Is my child really at risk 
for HPV?HPV is a very common infection in women and men that can cause 
cancer. Starting the vaccine series 
today will help protect your child 
from the cancers and diseases 
caused by HPV. 
I’m worried my child will 
think that getting this 
vaccine makes it OK to 
have sex.
Studies tell us that getting HPV 
vaccine doesn’t make kids more 
likely to start having sex. I made 
sure my child (or grandchild, 
etc.) got HPV vaccine, and I 
recommend we give your child 
her first HPV shot today.
I’m worried about the 
safety of HPV vaccine. 
Do you think it’s safe?
Yes, HPV vaccination is very safe. 
Like any medication, vaccines can 
cause side effects, including pain, 
swelling, or redness where the 
shot was given. That’s normal for 
HPV vaccine too and should go 
away in a day or two. Sometimes 
kids faint after they get shots and 
they could be injured if they fall 
from fainting. We’ll have your child 
stay seated after the shot to help 
protect him/her.
Can HPV vaccine cause 
infertility in my child?There is no evidence available to suggest that getting HPV vaccine 
will have an effect on future fertility. 
However, women who develop an 
HPV precancer or cancer could 
require treatment that would limit 
their ability to have children. CS269453B
Last updated MAY 2018
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Top 10 Tips for HPV
Vaccination Success 
Attain and Maintain High HPV Vaccination Rates
1 Appreciate the significance of achieving high HPV vaccination 
rates.
By boosting HPV vaccination rates among your patients, you will be preventing cancer.
2 Acknowledge the importance your recommendation has when it 
comes to parents choosing to get 
their children vaccinated.
Clinician recommendation is the number one reason parents decide to vaccinate. This is 
especially important for HPV vaccination.
3 Use an effective approach by bundling your vaccine 
recommendation.
Recommend the HPV vaccine the same day and the same way you recommend all other 
vaccines. For example, “Now that Danny is 11, he is due for vaccinations to help protect against 
meningitis, HPV cancers, and whooping cough. We’ll give those shots during today’s visit. Do 
you have any questions about these vaccines?”
4 Motivate your team and encourage their immunization 
conversations with parents.
Starting with your front office, ensure each team member is aware of HPV vaccine’s importance and is 
educated on proper vaccination practices and recommendations, ready to answer parents’ questions, 
and/or regularly remind and recall parents. Be sure staff regularly check immunization records, place 
calls to remind families about getting vaccines, and let you know if parents have additional questions.
5 Implement systems to ensure you never miss an opportunity to 
vaccinate.
Establish a policy to vaccinate at every visit. Create a system to check immunization status ahead 
of all visits. Before seeing the patient, staff should indicate if the patient is due for immunization, 
with special consideration to HPV vaccination. Use standing orders.
6 Use your local health department’s resources. Use the resources of the local health department to achieve your goals of protecting your patients.
7 Know your rates of vaccination and refusal. Deputize your staff to assist you with knowing your actual vaccination rates and learning more about why some patients are behind on their vaccines. They can also help you facilitate solutions 
on how to bring these patients in and get or keep immunization rates up.
8 Maintain strong doctor-patient relationships to help with challenging 
immunization conversations.
It is extremely gratifying when parents who initially questioned immunization agree to get their 
child vaccinated on time. It’s always nice to hear: “Okay, that makes sense and I trust you!”
9 Learn how to answer some of parents’ most common questions 
about HPV vaccine.
Be prepared to answer parents’ questions succinctly, accurately, and empathetically by using 
terms that they understand. A parent will often accept your explanations if presented with their 
children’s best interests in mind.
10 Use personal examples of how you choose to vaccinate children 
in your family.
Providing personal examples shows you believe in the importance of immunizations, especially 
HPV vaccine. These examples—combined with an effective recommendation—can help parents 
better understand the benefits of HPV vaccination for cancer prevention.
For more info visit: www.cdc.gov/hpv Last updated MAY 2018
Adapted with Permission from: Khatib, B. (2015) The 10 Immunization Success Factors: Practical Strategies for Providers. Unpublished manuscript.
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APPENDIX H. EXECUTIVE SUMMARY 
Background 
The human papillomavirus (HPV) infects millions of people every year in the United 
States (CDC, 2016a). A majority of the infections can be cleared without treatment; however, 
some have serious complications, including cancer. Cervical, oropharyngeal, anal, vulvar, 
vaginal, and penile cancers are all linked with recurrent HPV infections. Over 30,000 cases of 
HPV-positive cervical cancer are diagnosed annually in the United States. 
Fortunately, there is a vaccine to help reduce the rates of HPV infection and serious 
complications. The first HPV vaccine was released in 2006 and was a quadrivalent vaccine 
(CDC, 2016b). The current vaccine is nine-valent and provides protection against the most 
common and harmful serotypes of the HPV virus. The nine-valent vaccine was released in 2014. 
New 2-dose series recommendations were released by the ACIP in 2016 with hopes of increasing 
vaccination coverage in the United States (Meites, Kempe, & Markowitz, 2016). 
Increased vaccination coverage of at least 80% is one of the goals within Healthy People 
2020 (ODPHP, 2018). The coverage rates for the HPV vaccine lag behind the goal. The 1-dose 
coverage rate in North Dakota is 67.6% (CDC, 2017a). The lag in coverage is linked with missed 
opportunities for HPV vaccination, as well as a lack of provider recommendation. Provider 
recommendation for vaccination has been shown to be a critical factor (Hansen et al., 2016). 
McLean et al. (2017) found that rates of HPV vaccination increase after successful 
implementation of healthcare provider education. Healthcare providers must recommend 
vaccination at every visit to increase coverage rates (Zimmerman et al., 2016). 
Australia has had a HPV vaccination program since 2007 (Hall et al., 2018). Due to the 
program and their screening methods for cervical cancer, the rates of annual cervical cancer 
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diagnoses are decreasing. The rates are predicted to be less than 1% by the year 2020. By 2034, 
Australia is estimating a cervical cancer incidence of less than one per 100,000 cases annually. 
The vaccination program receives a large portion of the credit for this dramatic decrease, with 
HPV vaccination coverage rates at almost 80% for adolescent girls. 
Project Summary 
Based on the current HPV vaccination coverage statistics and research demonstrating the 
impact of provider recommendation and education, an educational practice improvement project 
was developed and implemented in rural North Dakota. Two rural family practice facilities were 
the setting for project implementation. The project was designed for all healthcare professionals, 
including physicians, advanced practice providers, nursing staff, and others. The purpose of the 
project was to enhance and increase healthcare professionals’ knowledge and level of comfort 
regarding HPV, the vaccine, and various communication strategies available to increase 
vaccination uptake and acceptance. Additionally, the project was designed to evaluate and reduce 
the rate of missed opportunities for HPV vaccination in rural family practice healthcare facilities. 
The educational presentation lasted approximately 60 minutes with time allowed for questions or 
comments and used a Power Point presentation format. 
Results 
Two evaluation methods were used for the project: a post-test and missed opportunity 
statistics. The post-test was provided immediately after attending the educational presentation. 
Thirty-three healthcare professionals participated in the project. A five-point Likert scale was 
used to evaluate the impact of the educational information on the healthcare professionals’ 
knowledge and level of comfort with new communication strategies. The average score for 
increased levels of knowledge after attending the presentation was 3.97. The average score for 
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the project increasing levels of comfort with new communication strategies was 4.06. The post-
test results suggest the project had a positive impact for the healthcare professionals who were 
able to attend. 
The results for missed opportunities for HPV vaccination at each of the locations were 
monitored for two months pre and post-educational intervention. The rates were broken into two 
age groups: 11-14 years and 15-26 years. The Valley City location did not have any reported 
missed opportunities before or after implementation. The Jamestown location did note missed 
opportunities but no significant change in rates post-intervention. The overall rate of missed 
opportunities for vaccination for the combined ages before was 30.3%. The post-intervention rate 
was 31.5% of missed opportunities. 
Frequent diagnoses associated with missed opportunities were also tracked. The rate of 
missed opportunities at routine exams, including physicals and well child exams, was 32 visits 
prior to implementation in Jamestown. The rate did decrease to 17 visits after the educational 
intervention. The number of HPV vaccines provided before and after project implementation 
remained steady. 
Recommendations 
The results of the post-test indication an increase in healthcare professionals’ knowledge 
and comfort with HPV vaccination and communication strategies. It is reasonable to recommend 
continued research into strategies to improve HPV vaccination coverage and reduce missed 
opportunities. Despite the lack of statistical findings supporting educational interventions 
reducing missed opportunities, further research into the impact of a multifaceted approach is 
needed. Educational interventions have been found to improve vaccination acceptance (Krantz et 
al., 2017). 
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One recommendation for future research is to include a multifaceted approach. The 
approach should include healthcare professional education, as well as provider feedback (Moore 
et al, 2017; Rand et al., 2018). Provider feedback methods are important for project sustainability 
as well. Additionally, the research should be over a longer period of time, as two months pre- 
and post-intervention was a limitation (Rand et al., 2018). 
The continued impact of the successful HPV vaccination program in Australia indicates a 
need for further research in the United States (Hall et al., 2018). Cervical cancer will be virtually 
eradicated in Australia by the year 2034. Vaccination coverage rates are steadily increasing as 
well. Further research into the sustainability of a program to reduce missed opportunities for 
vaccination and increase coverage is needed to decrease the impact of HPV-positive cancers in 
the United States and meet the Healthy People 2020 goal of over 80% coverage (ODPHP, 2018). 
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APPENDIX I. CENTER FOR DISEASE CONTROL AND PREVENTION — 
PERMISSION TO USE 
Ms. Hanson: 
  
The image is in the public domain. You just need to reference the source of the image in the 
presentation or any publication. 
  
Raymond A. Strikas, MD, MPH, FACP, FIDSA 
Lead, Education Team 
Communication and Education Branch 
Immunization Services Division 
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention 
1600 Clifton Road, NE, MS H24-6 
Ras8@cdc.gov 
Tel. 404 639 6465 
 
Carly, 
  
Thank you for your interest in the National Immunization Survey – Teen (NIS-Teen) data. You are 
welcome to use statistics, graphics, figures, etc from the CDC website. These are for public use. Please 
let me know if you have additional questions or need some other type of documentation of permission. 
Best Wishes with your dissertation! 
  
Laurie 
  
Laurie D. Elam-Evans, PhD, MPH 
Lead Health Scientist / Team Leader 
National Immunization Survey and National Immunization Survey-Teen 
Assessment Branch 
Immunization Services Division 
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention 
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APPENDIX J. NORTH DAKOTA DEPARTMENT OF HEALTH — PERMISSION TO 
USE 
Woinarowicz, Mary A. <mary.woinarowicz@nd.gov> 
Mon 3/26/2018, 9:09 AM 
Carly, 
 
Yes, you may use any of the maps and graphs for coverage rate information that is publicly available 
on our Immunization Program web site. Please just make sure to note that the source data is from the 
North Dakota Immunization Information System (NDIIS) and was analyzed by the NDIIS Manager of 
the ND Immunization Program.  
 
Mary Woinarowicz 
NDIIS Manager 
North Dakota Department of Health 
701.328.2404 
mary.woinarowicz@nd.gov 
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APPENDIX K. WOLTERS KLUWER HEALTH LICENSE — PERMISSION TO USE 
Thank you for your order! 
Dear Carly Hanson, 
Thank you for placing your order through Copyright Clearance Center’s 
RightsLink®service. 
 
Order Summary 
Licensee: Carly Hanson 
Order Date: Apr 22, 2019 
Order Number: 4574301386232 
Publication: book 
Title: Evidence-Based Practice in Nursing & Healthcare 
Type of Use: Dissertation/Thesis 
Order Total: 0.00 USD 
(Original Order Number: 501477392) 
View or print complete details of your order and the publisher's terms and 
conditions. 
 
 
Sincerely,  
 
Copyright Clearance Center 
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